<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="52967"><DrugName>apixaban</DrugName><DrugNamesKey><Name id="42939903">Eliquis</Name><Name id="42832902">apixaban</Name></DrugNamesKey><DrugSynonyms><Name><Value>razaxaban follow-on compound, Bristol-Myers Squibb/Pfizer</Value></Name><Name><Value>Factor Xa antagonist (follow-on), Bristol-Myers Squibb/Pfizer</Value></Name><Name><Value>BMS-562247</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>apixaban</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Eliquis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>503612-47-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesPrimary><Company id="18767">Pfizer Inc</Company><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesPrimary><CrossReferences><SourceEntity id="52967" type="Drug"><TargetEntity id="404724" type="siDrug">Apixaban</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="1542" type="ciIndication"><TargetEntity id="10003658" type="MEDDRA"></TargetEntity><TargetEntity id="D001281" type="MeSH"></TargetEntity><TargetEntity id="-1073626038" type="omicsDisease"></TargetEntity><TargetEntity id="194" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"></TargetEntity><TargetEntity id="-338631668" type="omicsDisease"></TargetEntity><TargetEntity id="306" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3258" type="ciIndication"><TargetEntity id="10051592" type="MEDDRA"></TargetEntity><TargetEntity id="D054058" type="MeSH"></TargetEntity><TargetEntity id="-489209930" type="omicsDisease"></TargetEntity><TargetEntity id="3262" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="120" type="Action"><TargetEntity id="6421" type="Mechanism">Anti-Factor Xa</TargetEntity><TargetEntity id="679" type="Mechanism">Coagulation Factor Xa Inhibitors</TargetEntity></SourceEntity><SourceEntity id="659" type="Action"><TargetEntity id="3176" type="Mechanism">Inhibitors of Blood Coagulation Pathways</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Thromboembolism - Germany - Jun-2011</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1542">Atrial fibrillation</Indication><Indication id="325">Thromboembolism</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="3258">Acute coronary syndrome</Indication></IndicationsSecondary><ActionsPrimary><Action id="120">Factor Xa antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="449">Antiarrhythmic agent</Action><Action id="659">Coagulation inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="746">Solution</Technology><Technology id="751">Film coating</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C1B</Code><Name>ANTI-ARRHYTHMICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-23T16:40:16.000Z</LastModificationDate><ChangeDateLast>2019-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2005-03-23T13:43:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) and &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt; have developed and launched the oral anticoagulant apixaban (BMS-562247; Eliquis), a follow-on compound to BMS's oral Factor Xa antagonist &lt;ulink linkID="32750" linkType="Drug"&gt;razaxaban&lt;/ulink&gt;. Apixaban is indicated in the EU for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery; the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF), with one or more risk factors, such as prior stroke or transient ischemic attack; age &amp;gt;/= 75 years, hypertension, diabetes mellitus symptomatic heart failure (NYHA Class &amp;gt;/= II); and for  the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults [&lt;ulink linkID="1221048" linkType="Reference"&gt;1221048&lt;/ulink&gt;], [&lt;ulink linkID="1580794" linkType="Reference"&gt;1580794&lt;/ulink&gt;]. In the US, the drug is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular AF;  for the prophylaxis of DVT, which may lead to  PE, in patients who have undergone hip or knee replacement surgery; and for the treatment of DVT and PE, and for the reduction of in the risk of recurrent DVT and PE following initial therapy  [&lt;ulink linkID="1353232" linkType="Reference"&gt;1353232&lt;/ulink&gt;]. It is indicated in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1352875" linkType="Reference"&gt;1352875&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By June 2011, apixaban was launched in Germany [&lt;ulink linkID="1338589" linkType="Reference"&gt;1338589&lt;/ulink&gt;], and by July 2011, the drug had been launched in a limited number of EU countries for the prevention of VTE in adults who had undergone elective hip or knee replacement [&lt;ulink linkID="1212066" linkType="Reference"&gt;1212066&lt;/ulink&gt;], [&lt;ulink linkID="1273838" linkType="Reference"&gt;1273838&lt;/ulink&gt;]. In September 2011, the drug was launched in the UK [&lt;ulink linkID="1353636" linkType="Reference"&gt;1353636&lt;/ulink&gt;]. In December 2011, the drug was launched in Sweden [&lt;ulink linkID="1408858" linkType="Reference"&gt;1408858&lt;/ulink&gt;]. In March 2014, apixaban was approved in the US for the prophylaxis of DVT, which could lead to PE, in patients who had undergone hip or knee replacement surgery [&lt;ulink linkID="1535365" linkType="Reference"&gt;1535365&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2013, apixaban was launched in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1386238" linkType="Reference"&gt;1386238&lt;/ulink&gt;]. By March 2013, apixaban was launched in the US and Europe for the reduction of risk of stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;], [&lt;ulink linkID="1449274" linkType="Reference"&gt;1449274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, the EC approved the drug in the EU for the treatment of DFVT and PE, and the prevention of recurrent DVT and PE in adults [&lt;ulink linkID="1580794" linkType="Reference"&gt;1580794&lt;/ulink&gt;]. In August 2014, apixaban was approved in the US for the treatment of VTE (DVT and PE), and for the reduction of in the risk of recurrent VTE (DVT and PE) following initial therapy [&lt;ulink linkID="1587013" linkType="Reference"&gt;1587013&lt;/ulink&gt;]. In December 2015, apixaban was approved in Japan for the treatment and recurrence inhibition of venous thromboembolism (DVT and PE) [&lt;ulink linkID="1722793" linkType="Reference"&gt;1722793&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;BMS and Pfizer were previously  developing the drug for the prevention of cardiovascular events in patients with  acute coronary syndrome (ACS). In March 2009, a phase III trial in ACS was initiated [&lt;ulink linkID="1079593" linkType="Reference"&gt;1079593&lt;/ulink&gt;], [&lt;ulink linkID="1090839" linkType="Reference"&gt;1090839&lt;/ulink&gt;]; however, in November 2010, development for ACS was discontinued after the APPRAISE-2 study showed an increase in bleeding in apixaban-treated patients [&lt;ulink linkID="1149245" linkType="Reference"&gt;1149245&lt;/ulink&gt;]. BMS and Pfizer were also developing the drug for the prevention of VTE in cancer patients and medically ill patients (phase III trials began in June 2006 and June 2007, respectively [&lt;ulink linkID="924955" linkType="Reference"&gt;924955&lt;/ulink&gt;], [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;]); in July 2009 and November 2011, respectively, data were reported, with negative results in   medically ill patients [&lt;ulink linkID="1043634" linkType="Reference"&gt;1043634&lt;/ulink&gt;], [&lt;ulink linkID="1239221" linkType="Reference"&gt;1239221&lt;/ulink&gt;]; no development has been reported since that time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;NCE exclusivity expired in December 2017. There are two constraining US product patents (&lt;ulink linkID="PA3163827" linkType="Patent"&gt;US-06413980&lt;/ulink&gt; and &lt;ulink linkID="PA3062604" linkType="Patent"&gt;US-06967208&lt;/ulink&gt;), which expire in December 2019 and February 2023, respectively. By February 2016, BMS had requested the USPTO grant patent term restoration for US-06967208 to December 2026   [&lt;ulink linkID="1735637" linkType="Reference"&gt;1735637&lt;/ulink&gt;]; by February 2018, the patent had been extended to November 2026 [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt; received tentative approval for its apixaban tablets, 2.5 and 5 mg from the FDA [&lt;ulink linkID="2102955" linkType="Reference"&gt;2102955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2017, 25 generic companies had filed an ANDA for the approval of their generic versions of apixaban, challenging two Orange book listed patents covering the composition of matter and the formulation. In April 2017, BMS and Pfizer initiated patent lawsuits under the Hatch-Waxman Act against all generic filers in federal district courts in Delaware and West Virginia. In August 2017, the US Patent and Trademark Office granted patent term restoration to the composition of matter patent. By February 2018, BMS had settled lawsuits with several ANDA filers [&lt;ulink linkID="2005764" linkType="Reference"&gt;2005764&lt;/ulink&gt;]. In February 2018, Pfizer noted that the challenged patents were a total of three Orange-book-listed patents expiring in 2019, 2026, and 2031; some ANDA filers  had challenged only the 2031 patent, some had challenged both the 2031 and 2026 patent, and one generic company had challenged all three patents [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;]. By December 2018, BMS had settled lawsuits with a number of ANDA filers [&lt;ulink linkID="2123173" linkType="Reference"&gt;2123173&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2015, BMS received a Petition for Inter Partes Review of the drug's composition of matter patent (&lt;ulink linkID="PA3062604" linkType="Patent"&gt;US-06967208&lt;/ulink&gt;) filed by the Coalition for Affordable Drugs. In November 2015, BMS opposed the petition. In February 2016, BMS  [&lt;ulink linkID="1735637" linkType="Reference"&gt;1735637&lt;/ulink&gt;]; later that month, the PTAB rejected the petition and declined to review the patent [&lt;ulink linkID="1745372" linkType="Reference"&gt;1745372&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;The EU composition of matter patent expires in 2022 [&lt;ulink linkID="1641439" linkType="Reference"&gt;1641439&lt;/ulink&gt;]. SPCs on &lt;ulink linkID="PA3326117" linkType="Patent"&gt;EP-01427415&lt;/ulink&gt; have been granted in most EU countries, including the UK, France and Spain, that expire in May 2026. EU data exclusivity expires in 2021. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;The Japanese composition of matter patent expires in 2026, including a granted patent term extension [&lt;ulink linkID="1735637" linkType="Reference"&gt;1735637&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In February 2017, &lt;ulink linkID="1017684" linkType="Company"&gt;Jiangsu Hansoh Pharmaceutical Group&lt;/ulink&gt; filed an ANDA for its generic version of apixaban tablets in China [&lt;ulink linkID="2001523" linkType="Reference"&gt;2001523&lt;/ulink&gt;]. In January 2018, the application was granted Priority Review for the first generic variety in China [&lt;ulink linkID="2000737" linkType="Reference"&gt;2000737&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;The composition of matter patent expires in Canada in 2022 [&lt;ulink linkID="1392809" linkType="Reference"&gt;1392809&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By October 2010, BMS and Pfizer had initiated a rolling NDA submission to the FDA, for the prevention of stroke in AF patients not suitable to &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt; treatment [&lt;ulink linkID="1146782" linkType="Reference"&gt;1146782&lt;/ulink&gt;]. In November 2011, the NDA was accepted for Priority Review by the FDA, with a PDUFA date of March 28, 2012 [&lt;ulink linkID="1244044" linkType="Reference"&gt;1244044&lt;/ulink&gt;]. In February 2012, the PDUFA date was extended to June 28, 2012 due to the submission of additional information that was considered a major amendment to the application [&lt;ulink linkID="1267730" linkType="Reference"&gt;1267730&lt;/ulink&gt;]. In June 2012, the FDA issued a Complete Response letter requesting additional information on the management and verification of data from the ARISTOTLE trial [&lt;ulink linkID="1303887" linkType="Reference"&gt;1303887&lt;/ulink&gt;]; no new studies were required [&lt;ulink linkID="1310918" linkType="Reference"&gt;1310918&lt;/ulink&gt;]. In September 2012, the NDA was resubmitted with additional data in response to the agency's request; at that time, a new PDUFA date was set for March 17, 2013 [&lt;ulink linkID="1326712" linkType="Reference"&gt;1326712&lt;/ulink&gt;]. In December 2012, the drug was approved in patients with non-valvular AF  [&lt;ulink linkID="1353214" linkType="Reference"&gt;1353214&lt;/ulink&gt;], [&lt;ulink linkID="1353217" linkType="Reference"&gt;1353217&lt;/ulink&gt;]; in January 2013, launch was expected by the end of that month [&lt;ulink linkID="1387894" linkType="Reference"&gt;1387894&lt;/ulink&gt;]; by March 2013, the product had been launched [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;], [&lt;ulink linkID="1449274" linkType="Reference"&gt;1449274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, regulatory filings for the long-term treatment of VTE and extended prevention of recurrent VTE were planned, based on data from the  and AMPLIFY-EXT trials [&lt;ulink linkID="1446182" linkType="Reference"&gt;1446182&lt;/ulink&gt;]. In December 2013, the FDA accepted the submission of an sNDA for the treatment of VTE (DVT and PE), and for the reduction in the risk of recurrent VTE (DVT and PE); at that time, the PDUFA date was August 25, 2014 [&lt;ulink linkID="1510643" linkType="Reference"&gt;1510643&lt;/ulink&gt;]. In August 2014, approval was granted in the US for VTE [&lt;ulink linkID="1587013" linkType="Reference"&gt;1587013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, supported by data from the ADVANCE-1, ADVANCE-2 and ADVANCE-3 trials in VTE, the  FDA accepted the submission of an sNDA for the prevention of VTE in adults who had undergone hip or knee replacement; at that time, the PDUFA  data was March 15, 2014 [&lt;ulink linkID="1451337" linkType="Reference"&gt;1451337&lt;/ulink&gt;]. In March 2014, approval was granted in the US for the prophylaxis of DVT, which could lead to PE, in patients who had undergone hip or knee replacement surgery [&lt;ulink linkID="1535365" linkType="Reference"&gt;1535365&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2010, the companies filed an MAA for the prevention of VTE events in adults who had undergone elective hip or knee replacement [&lt;ulink linkID="1094869" linkType="Reference"&gt;1094869&lt;/ulink&gt;]; in March 2011, the CHMP recommended approval [&lt;ulink linkID="1177608" linkType="Reference"&gt;1177608&lt;/ulink&gt;]. In May 2011, the drug was approved in the EU for the prevention of VTE in adults who had undergone elective hip or knee replacement [&lt;ulink linkID="1193644" linkType="Reference"&gt;1193644&lt;/ulink&gt;]. By June 2011, apixaban was launched in Germany [&lt;ulink linkID="1338589" linkType="Reference"&gt;1338589&lt;/ulink&gt;]; by July 2011, the drug had been launched in a limited number of EU countries [&lt;ulink linkID="1212066" linkType="Reference"&gt;1212066&lt;/ulink&gt;], [&lt;ulink linkID="1273838" linkType="Reference"&gt;1273838&lt;/ulink&gt;]. In September 2011, the drug was launched in the UK [&lt;ulink linkID="1353636" linkType="Reference"&gt;1353636&lt;/ulink&gt;]. In October 2011, the drug was launched in Switzerland [&lt;ulink linkID="1570879" linkType="Reference"&gt;1570879&lt;/ulink&gt;]. In December 2011, the drug was launched in Sweden [&lt;ulink linkID="1408858" linkType="Reference"&gt;1408858&lt;/ulink&gt;]. In July 2012, the drug was launched in France [&lt;ulink linkID="1347648" linkType="Reference"&gt;1347648&lt;/ulink&gt;]. By May 2013, the drug was launched in the Netherlands [&lt;ulink linkID="1435535" linkType="Reference"&gt;1435535&lt;/ulink&gt;]. By June 2013, the drug was launched in the Czech Republic [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. By July 2013, apixaban was also approved in Norway and Iceland [&lt;ulink linkID="1451337" linkType="Reference"&gt;1451337&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a filing for stroke prevention in patients with AF was validated for review by the EMA [&lt;ulink linkID="1239221" linkType="Reference"&gt;1239221&lt;/ulink&gt;], [&lt;ulink linkID="1273551" linkType="Reference"&gt;1273551&lt;/ulink&gt;]; in September 2012, the CHMP issued a positive opinion [&lt;ulink linkID="1325422" linkType="Reference"&gt;1325422&lt;/ulink&gt;], [&lt;ulink linkID="1325415" linkType="Reference"&gt;1325415&lt;/ulink&gt;], [&lt;ulink linkID="1326712" linkType="Reference"&gt;1326712&lt;/ulink&gt;]. In November 2012, approval was granted by the EC [&lt;ulink linkID="1342790" linkType="Reference"&gt;1342790&lt;/ulink&gt;]. In February 2013, apixaban was approved in Russia for the reduction of risk of stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;]. By March 2013, the drug had been launched in Europe for  the reduction of risk of stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;], [&lt;ulink linkID="1449274" linkType="Reference"&gt;1449274&lt;/ulink&gt;]; by April 2013, the product was launched in the UK, Germany and Denmark  [&lt;ulink linkID="1412952" linkType="Reference"&gt;1412952&lt;/ulink&gt;]. By July 2013, apixaban was also approved for this indication in Norway and Iceland [&lt;ulink linkID="1451337" linkType="Reference"&gt;1451337&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, regulatory filings for the long-term treatment of VTE and extended prevention of recurrent VTE were planned, based on data from the AMPLIFY and AMPLIFY-EXT trials [&lt;ulink linkID="1446182" linkType="Reference"&gt;1446182&lt;/ulink&gt;]. In November 2013, the EMA accepted for review an application for the treatment of VTE (DVT and PE) and for the prevention of recurrent VTE (DVT and PE) [&lt;ulink linkID="1510643" linkType="Reference"&gt;1510643&lt;/ulink&gt;]. In March 2014, approval of the drug for the treatment of VTE was expected in 2014 [&lt;ulink linkID="1534044" linkType="Reference"&gt;1534044&lt;/ulink&gt;]. In June 2014, the CHMP  adopted a positive opinion recommending approval of the drug for use in the treatment of treatment of DVT and PE, and the prevention of recurrent DVT and PE, in adults [&lt;ulink linkID="1573390" linkType="Reference"&gt;1573390&lt;/ulink&gt;]. In July 2014, the EC approved the drug in the EU, Iceland and Norway for the treatment of DVT and PE, and the prevention of recurrent DVT and PE, in adults [&lt;ulink linkID="1580794" linkType="Reference"&gt;1580794&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In December 2011, a filing was submitted for the prevention of stroke in patients with AF [&lt;ulink linkID="1253896" linkType="Reference"&gt;1253896&lt;/ulink&gt;]. In November 2012, the Pharmaceuticals Affairs and Food Sanitation Council's First Committee on Drugs was to review the application at a meeting on November 30, 2012 [&lt;ulink linkID="1343251" linkType="Reference"&gt;1343251&lt;/ulink&gt;]; at the meeting the committee recommended approval [&lt;ulink linkID="1347510" linkType="Reference"&gt;1347510&lt;/ulink&gt;]. In December 2012, apixaban was approved in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1352875" linkType="Reference"&gt;1352875&lt;/ulink&gt;]; in February 2013, the product was launched in Japan [&lt;ulink linkID="1386238" linkType="Reference"&gt;1386238&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, a supplemental regulatory submission for the treatment and recurrence inhibition of venous thromboembolism (DVT and PE) was filed in Japan [&lt;ulink linkID="1634911" linkType="Reference"&gt;1634911&lt;/ulink&gt;]; in December 2015, apixaban was approved in Japan for that indication [&lt;ulink linkID="1722793" linkType="Reference"&gt;1722793&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In July 2011, an NDA was filed with the SFDA [&lt;ulink linkID="1390798" linkType="Reference"&gt;1390798&lt;/ulink&gt;]; in December 2012, this product was approved in China [&lt;ulink linkID="1384044" linkType="Reference"&gt;1384044&lt;/ulink&gt;];  in April 2013, the  product was launched in China for the prevention of VTE in adults who had undergone elective hip or knee replacement [&lt;ulink linkID="1404225" linkType="Reference"&gt;1404225&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In 2011, the drug was approved in Canada for preventing VTE in adults who had undergone elective total hip or knee replacement surgery [&lt;ulink linkID="1616056" linkType="Reference"&gt;1616056&lt;/ulink&gt;]. In December 2012, apixaban was approved in Canada for the prevention of stroke and systemic embolism in patients with AF [&lt;ulink linkID="1348790" linkType="Reference"&gt;1348790&lt;/ulink&gt;]. By March 2013, the drug was launched in Canada  [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;], [&lt;ulink linkID="1449274" linkType="Reference"&gt;1449274&lt;/ulink&gt;]. In November 2014, the drug was approved in Canada for treating VTE and for preventing recurrent DVT and PE [&lt;ulink linkID="1616056" linkType="Reference"&gt;1616056&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By December 2015, the product was available in Puerto Rico [&lt;ulink linkID="2073455" linkType="Reference"&gt;2073455&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, the product was approved in Argentina [&lt;ulink linkID="2073486" linkType="Reference"&gt;2073486&lt;/ulink&gt;]; launch was presumed to have occurred shortly after.&lt;/para&gt;&lt;para&gt;By March 2012, launch in Mexico was expected within the next 2 years  [&lt;ulink linkID="1273838" linkType="Reference"&gt;1273838&lt;/ulink&gt;]. In April 2013, apixaban was approved in Mexico for the reduction of risk of stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;]; it is presumed that launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By March 2012, launch  in Brazil was expected by 2015 [&lt;ulink linkID="1273838" linkType="Reference"&gt;1273838&lt;/ulink&gt;]. In July 2013, apixaban was approved in Brazil for the prevention of stroke in adult patients with non-valvular AF; it is presumed that launch occurred shortly following approval. By that time, the drug was already launched in Brazil for VTE in patients undergoing total knee and hip arthroplasty  [&lt;ulink linkID="2038395" linkType="Reference"&gt;2038395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, apixaban was approved in Colombia for the reduction of risk of stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1410186" linkType="Reference"&gt;1410186&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In  July 2014, apixaban was approved in Turkey [&lt;ulink linkID="2071744" linkType="Reference"&gt;2071744&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="2073473" linkType="Reference"&gt;2073473&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a regulatory filing was submitted in Turkey. In May 2017, approval was granted [&lt;ulink linkID="2073515" linkType="Reference"&gt;2073515&lt;/ulink&gt;]; launch was presumed to have occurred shortly after. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;By March 2012, launch in India was expected within the next 2 years  [&lt;ulink linkID="1273838" linkType="Reference"&gt;1273838&lt;/ulink&gt;]. By September 2018, the product was available in India [&lt;ulink linkID="2073459" linkType="Reference"&gt;2073459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By September 2018, the product was available in Hong Kong [&lt;ulink linkID="2073520" linkType="Reference"&gt;2073520&lt;/ulink&gt;], Malaysia [&lt;ulink linkID="2073526" linkType="Reference"&gt;2073526&lt;/ulink&gt;], the Philippines [&lt;ulink linkID="2073527" linkType="Reference"&gt;2073527&lt;/ulink&gt;], Singapore [&lt;ulink linkID="2073529" linkType="Reference"&gt;2073529&lt;/ulink&gt;], .&lt;/para&gt;&lt;para&gt;In July 2011, apixaban (2.5-mg strength) was approved in Australia for the prevention of VTE in adults who have undergone elective hip or knee replacement surgery. In April 2013, a 5-mg strength tablet was approved and the approved indications were extended to include the prevention of stroke and systemic embolism in patients with non-valvular AF [&lt;ulink linkID="1470730" linkType="Reference"&gt;1470730&lt;/ulink&gt;]. By October 2013, the drug had been launched in Australia [&lt;ulink linkID="1494583" linkType="Reference"&gt;1494583&lt;/ulink&gt;]. In May 2015, the product was approved by the TGA for the treatment of DVT and PE and the prevention of recurrent DVT and PE in adult patients [&lt;ulink linkID="1718116" linkType="Reference"&gt;1718116&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, apixaban was filed for approval in South Korea. In May 2012, the companies were planning to launch the agent by the end of that year [&lt;ulink linkID="1299948" linkType="Reference"&gt;1299948&lt;/ulink&gt;].  In January 2013, approval was granted in South Korea  for prevention of stroke and systemic embolism in patients with nonvalvular AF [&lt;ulink linkID="1362792" linkType="Reference"&gt;1362792&lt;/ulink&gt;]. In May 2013, the agent was included in the country's list of reimbursed drugs [&lt;ulink linkID="1464175" linkType="Reference"&gt;1464175&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;In August 2013, the drug was approved as Eliquis film-coated tablets in Taiwan for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation. The product was assumed to be launched shortly after  [&lt;ulink linkID="1523066" linkType="Reference"&gt;1523066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label contains a black box warning stating that discontinuing apixaban in patients without adequate continuous anticoagulation increases the risk of stroke, and warning of the risk of spinal/epidural hematoma [&lt;ulink linkID="1353232" linkType="Reference"&gt;1353232&lt;/ulink&gt;]. In January 2019, the EMA's CHMP was reviewing data from  an observational study (ARISTOPHANES) of &lt;ulink linkID="24343" linkType="Drug"&gt;dabigatran etexilate&lt;/ulink&gt;, apixaban and &lt;ulink linkID="32677" linkType="Drug"&gt;rivaroxaban&lt;/ulink&gt;, that was assessing  the risk of major bleedings when those drugs were used to prevent blood clotting in patients with non-valvular AF, to determine whether the results of the study had implications on the use of the drug [&lt;ulink linkID="2116194" linkType="Reference"&gt;2116194&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In November 2018, data from the largest real-world data analysis of non-valvular AF patient populations aged 80 and older receiving direct oral anticoagulants. Eliquis was demonstrated to be associated with lower rates of stroke or systemic embolism and major bleeding than &lt;ulink linkID="32677" linkType="Drug"&gt;rivaroxaban&lt;/ulink&gt; or &lt;ulink linkID="24343" linkType="Drug"&gt;dabigatran&lt;/ulink&gt; [&lt;ulink linkID="2123173" linkType="Reference"&gt;2123173&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2016, an interventional, parallel assignment, randomized, phase IV (&lt;ulink linkID="278673" linkType="Protocol"&gt;NCT02958969&lt;/ulink&gt;) to evaluate safety and efficacy of apixaban was initiated at Brigham and Womens Hospital in collaboration with Bristol-Myers Squibb in US for prevention of venous thromboembolism (VTM) in multiple myeloma patients (n = 50) on Immunomodulatory/cereblon-binding drug therapy. The primary endpoint was symptomatic VTE and major and clinically relevant non-major bleeding. Secondary endpoint was all-cause mortality and atherothrombotic events. At the time of presentation first interim analysis data were presented at 2018 [&lt;ulink linkID="2114536" linkType="Reference"&gt;2114536&lt;/ulink&gt;]. In December 2018, 3-months interim analysis data of 50 patients were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. There was no incidence of major bleeding, venous thromboembolism, superficial vein thrombosis, myocardial infarction, stroke or transient ischemic attack. Clinically relevant, non-major bleeding events were observed in three patients (6%), including one patient who experienced unprovoked epistaxis lasting more than 5 min, one patient with mechanical trauma and another patient with arm ecchymoses. A patient stopped therapy shortly after initiation because of allergic reaction to apixaban manifesting as generalized edema. Overall, low dose apixaban was safe and well tolerated as thromboprophylaxis  [&lt;ulink linkID="2098621" linkType="Reference"&gt;2098621&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, data were presented from a  retrospective, observational cohort analysis of non-valvular AF patients (n = 162,707) from the ongoing ARISTOPHANES real-world data analysis initiative at the 67th Annual Meeting of the American College of Cardiology in Orlando, FL, These data showed a significant lower rate of both stroke/systemic embolism (S/SE) (p = 0.004) and major bleeding (MB) (p = &amp;lt; 0.001) when compared to &lt;ulink linkID="32677" linkType="Drug"&gt;rivaroxaban&lt;/ulink&gt;; and significantly lower rates of both S/SE (p = &amp;lt; 0.001) and MB (p = &amp;lt; 0.001) when compared with &lt;ulink linkID="24343" linkType="Drug"&gt;dabigatran&lt;/ulink&gt;. The study included three cohorts: apixaban versus rivaroxaban (n =125,238), apixaban versus dabigatran (n = 54,192), and dabigatran versus rivaroxaban (n = 55,076) [&lt;ulink linkID="2012283" linkType="Reference"&gt;2012283&lt;/ulink&gt;]. In August 2018, further data were presented at 2018 ESC Congress in Munich, Germany. Compared to those who initiated dabigatran and rivaroxaban, apixaban had  a  significantly  lower  risk  of  stroke/SE (hazard ratio: 0.69, 0.80 and 1.15, respectively, p &amp;lt; 0.001,  &amp;lt; 0.001 and 0.121, respectively),  after  propensity score matching (PSM). Patients who initiated apixaban and dabigatran had a significantly lower risk of major bleeding (MB) than with rivaroxaban, after matching (HR 0.77, 0.55 and 0.70, respectively, p &amp;lt; 0.001 each) [&lt;ulink linkID="2065764" linkType="Reference"&gt;2065764&lt;/ulink&gt;]. Further data were presented at same conference. Apixaban,  dabigatran  or  rivaroxaban   use were associated with lower rates of stroke/SE and varying comparative rates of MB compared with warfarin in a pooled analysis of US non-valvular atrial fibrillation [&lt;ulink linkID="2065799" linkType="Reference"&gt;2065799&lt;/ulink&gt;]. Further data were presented at same conference. After propensity score matching (PSM), patients who received standard- and lower-dose of apixaban were each associated with lower rates of S/SE and MB versus warfarin (standard dose: HR 0.68 and 0.64, respectively, lower dose: 0.62 and 0.57, respectively)  [&lt;ulink linkID="2065793" linkType="Reference"&gt;2065793&lt;/ulink&gt;]. Further data were presented at same conference. In patients received standard dose of apixaban were associated with similar rates of strokes (S)/systemic embolism (SE), but a significantly lower rate of major bleeding (MB) versus standard-dose dabigatran, and lower-dose apixaban patients had a lower rate of S/SE and MB versus lower-dose dabigatran (standard dose: hazard ratio (HR) 0.79 and 0.85, respectively, lower dose: 0.64 and 0.60, respectively) [&lt;ulink linkID="2065830" linkType="Reference"&gt;2065830&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data from a clinical study were presented at ASN's Kidney Week 2016 in Chicago, IL. Patients (n = 7; five were Caucasian, one Asian and one Afro-Caribbean) in received apixaban (2.5 mg, bid) on day 1 (phase I part) and 8 followed by dialysis on day 9 (phase II part) with a washout period on day 10 to 14 and then apixaban (5 mg, bid) on day 15 (phase III; day 15 to 22). In apixaban (2.5 mg bid) group, AUC (0 to 12) was 298.6 and 1009.8 ng.h/ml; AUC (0 to 24) was 597.3 and 2019.7 ng h/ml; Cmax was 45.2 and 131.5 ng/ml; Tmax was 4.4 and 3.6 h; C trough was 22.3 and 58.3 ng/ml; t1/2 was 5.9 and 7.5 h, at day 1 and 8, respectively. In apixaban 5 mg bid group, AUC (0 to 12), AUC (0 to 24), Cmax, Tmax, Ctrough and t1/2 was 3026.6 ng.h/ml, 6053.2 ng.h/ml, 307.0 ng/ml, 3.8 h, 217.5 ng/ml and 17.4 h, respectively, on day 8. Minor bleeding event was experienced by a patient receiving apixaban 5 mg dose  [&lt;ulink linkID="1877012" linkType="Reference"&gt;1877012&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2016, clinical data from an open-label, AEGEAN study were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. Patients were randomized to receive apixaban with primary standard of care (SOC; n = 583; arm 1) or with additional educational program (AEP; n = 579; arm 2) for 24 weeks in part I and patients in arm 2 were further randomized to receive apixaban with secondary SOC (n = 236) or continued additional educational program (n = 261) in part II. In part I, adherence (primary endpoint) was 91.9 and 91.6% in patients receiving apixaban with AEP and SOC, respectively, at week 24. In part II, mean adherence was 90.4, 89.3 and 90.1% in apixaban-treated patients with continued AEP, secondary SOC and primary SOC, respectively. At week 48, persistence was observed in 86.1, 85.2 and 87.8% of apixaban-treated patients with continued AEP, primary SOC and secondary SOC, respectively [&lt;ulink linkID="1872119" linkType="Reference"&gt;1872119&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2015, an open-label, two-by-two factorial, randomized controlled, phase IV trial (&lt;ulink linkID="227535" linkType="Protocol"&gt;NCT02415400&lt;/ulink&gt;; CV185-316; 2014-002004-24; AUGUSTUS) was initiated to assess the safety of apixaban versus vitamin K antagonist  and aspirin versus aspirin placebo in patients (expected n = 4600) with nonvalvular AF and a recent ACS or undergoing percutaneous coronary intervention (PCI) from 30 countries. The coprimary endpoints were time to first occurrence of ISTH major/clinically relevant non-major  bleeding during the treatment period between apixaban and vitamin K antagonist at 6 months, and time to first occurrence of major or clinically relevant non-major  bleeding during the treatment period between no aspirin and aspirin at approximately 6 months. At that time, the study was expected to complete in September 2017 [&lt;ulink linkID="1693486" linkType="Reference"&gt;1693486&lt;/ulink&gt;]. In September 2015, the first patient was enrolled  [&lt;ulink linkID="1693131" linkType="Reference"&gt;1693131&lt;/ulink&gt;]. In March 2019, data were presented at the American College of Cardiology's 68th Annual Scientific Session 2019 in New Orleans, LA and simultaneously published. Data from 4614 patients showed that in patients who received a P2Y12 inhibitor with or without aspirin, the proportion of patients with major or clinically relevant non-major (CRNM) bleeding at six months was significantly lower for those treated with apixaban compared to those treated with a vitamin K antagonists (10.5% versus 14.7%, respectively; HR: 0.69, 95% CI: 0.58-0.81; p-superiority &amp;lt; 0.001).  Independent of the apixaban versus vitamin K antagonists comparison, results also showed that in patients who received a P2Y12 inhibitor and an anticoagulant, the proportion of patients with major or CRNM bleeding at six months was significantly higher for those receiving aspirin compared to those receiving placebo (16.1% versus 9.0%, respectively; HR: 1.89, 95%CI: 1.59-2.24; p&amp;lt;0.001). At six months, patients who received a P2Y12 inhibitor with or without aspirin who were treated with apixaban had lower rates of death or hospitalization (23.5% versus 27.4%, respectively; HR: 0.83, 95% CI: 0.74-0.93; p=0.002) and similar rates of death or ischemic events (6.7% versus 7.1%, respectively; HR: 0.93, 95% CI: 0.75-1.16; p=NS) compared to those assigned to vitamin K antagonists. Patients who received a P2Y12 inhibitor and an anticoagulant who were treated with aspirin had similar rates of death or hospitalization (26.2% versus 24.7%, respectively; HR: 1.08, 95% CI: 0.96-1.21; p=NS) and similar rates of death or ischemic events (6.5% versus 7.3%, respectively; HR: 0.89, 95% CI: 0.71-1.11) compared to the placebo arm [&lt;ulink linkID="2130475" linkType="Reference"&gt;2130475&lt;/ulink&gt;], [&lt;ulink linkID="2130561" linkType="Reference"&gt;2130561&lt;/ulink&gt;], [&lt;ulink linkID="2130925" linkType="Reference"&gt;2130925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  February 2015, a prospective, observational, early post-marketing study (&lt;ulink linkID="193625" linkType="Protocol"&gt;NCT02153424&lt;/ulink&gt;; CV185-330) was initiated in Mexico, in patients (expected n = 50) with AF, to identify adverse effects. At that time, the trial was expected to complete in June 2016 [&lt;ulink linkID="1637228" linkType="Reference"&gt;1637228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, a prospective,  early post-marketing study (&lt;ulink linkID="220537" linkType="Protocol"&gt;NCT02345343&lt;/ulink&gt;; CV185-399)   was scheduled to begin in Mexico, in April 2015, in patients (expected n = 100) with  DVT and PE. At that time, the trial was expected to complete in February 2017 [&lt;ulink linkID="1629782" linkType="Reference"&gt;1629782&lt;/ulink&gt;]. In June 2015, the trial was initiated [&lt;ulink linkID="1629782" linkType="Reference"&gt;1629782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, an investigator-driven, prospective, parallel-group, randomised, open, blinded outcome assessment (PROBE), multi-centre phase IV trial (&lt;ulink linkID="209669" linkType="Protocol"&gt;NCT02227550&lt;/ulink&gt;; AFNET 5 AXAFA; 2014-002442-45) to compare anticoagulation with apixaban and vitamin-K-antagonists (VKA) therapy  in the prevention of peri-procedural complications in patients (n = 676) undergoing catheter ablation of non-valvular AF. The study was completed in September 2017 [&lt;ulink linkID="2015622" linkType="Reference"&gt;2015622&lt;/ulink&gt;]. In March 2018, findings from the study were presented at the European Heart Rhythm Association Congress in Barcelona, Spain. The investigators found a small but statistically significant improvement in cognitive function in both study groups at the end of the study [&lt;ulink linkID="2015418" linkType="Reference"&gt;2015418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, a parallel, randomized, phase IV study  (&lt;ulink linkID="219175" linkType="Protocol"&gt;UMIN000015923&lt;/ulink&gt;) comparing the safety and efficacy of apixaban  versus  dual antiplatelet treatment (aspirin and clopidogrel) was planned to be initiated, in April 2015, in patients (expected n = 600) with atrial fibrillation, who underwent drug-eluting stent implantation [&lt;ulink linkID="1624280" linkType="Reference"&gt;1624280&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2014, a randomized, open-label, phase IV  trial (&lt;ulink linkID="179946" linkType="Protocol"&gt;NCT02100228&lt;/ulink&gt;; B0661025; CV185-267; EMANATE) comparing the safety and efficacy of apixaban  versus standard care (parenteral heparin and/or oral anticoagulation with a vitamin K antagonist) began in patients (expected n = 1500) with non-valvular AF undergoing cardioversion in the US and Canada. The primary endpoint included the occurrence of acute stroke, systemic embolism, all-cause death, major bleeding and clinically relevant non-major bleeding. At that time, the first patient was enrolled [&lt;ulink linkID="1578094" linkType="Reference"&gt;1578094&lt;/ulink&gt;], [&lt;ulink linkID="1578313" linkType="Reference"&gt;1578313&lt;/ulink&gt;]. In August 2017, data were presented at the 2017 ESC congress in Barcelona, Spain. Fewer strokes were seen in patients receiving apixaban (n = 0) compared to standard of care (n = 6; p = 0.01); similar bleeding rates were noted and no systemic embolic events were seen. There were major bleeds in 3 and 6 patients, respectively, with clinically significant non-major bleeding in 11 and 13 patients, respectively. There were 2 deaths on apixaban compared with 1 in usual care. Patients that received a loading dose of apixaban (n = 342/753) no strokes or systemic embolic events were seen, with 1 death, 1 major bleed and 4 clinically relevant non-major bleeds [&lt;ulink linkID="1956720" linkType="Reference"&gt;1956720&lt;/ulink&gt;],  [&lt;ulink linkID="1957682" linkType="Reference"&gt;1957682&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2014, data  presented from a real world study at the 63rd Annual Meeting of the American College of Cardiology in Washington DC, showed apixaban to have a lower discontinuation rate than  warfarin, dabigatran and rivaroxaban in patients with atrial fibrillation [&lt;ulink linkID="1542295" linkType="Reference"&gt;1542295&lt;/ulink&gt;]. In November 2015, further clinical data from the retrospective cohort study which compared the first major bleeding event risk in patients (n = 26604) with non valvular atrial fibrillation who newly initiated on dose-adjusted warfarin versus apixaban (5 mg, bid), dabigatran (150 mg, bid) or rivaroxaban (20 mg, qd) were presented at the AHA's Scientific Sessions 2015 in Orlando, FL. Patients who were on apixaban 5 mg bid had significantly lower risk of major bleeding compared with patients who were on warfarin with hazard ratios of 0.53 versus 1.00, respectively [&lt;ulink linkID="1711463" linkType="Reference"&gt;1711463&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By June 2010, apixaban was being evaluated in the EXPANSE clinical program,  consisting of nine randomized, double-blind studies which were to include up to 60,000 patients across multiple indications [&lt;ulink linkID="1107594" linkType="Reference"&gt;1107594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Venous thromboembolism prevention in hip replacement&lt;/subtitle&gt;In March 2007, a phase III trial (&lt;ulink linkID="7849" linkType="Protocol"&gt;NCT00423319&lt;/ulink&gt;; CV185-035; ADVANCE-3) in patients undergoing elective total hip replacement surgery began. In the randomized, double-blind, multinational study,  5406 patients were to receive placebo plus 2.5 mg of apixaban twice daily or 40 mg of &lt;ulink linkID="13928" linkType="Drug"&gt;enoxaparin&lt;/ulink&gt; once daily for 5 weeks. The primary endpoints included asymptomatic and symptomatic DVT, non-fatal PE and all-cause death. Secondary endpoints included proximal DVT, non-fatal PE,  VTE-related death, major and minor bleeding events. The trial completed in September 2009  [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;], [&lt;ulink linkID="915533" linkType="Reference"&gt;915533&lt;/ulink&gt;].  In July 2010, data were first presented at the 21st International Congress on Thrombosis in Milan, Italy, and in December 2010, the data were published, which demonstrated that apixaban was statistically superior to enoxaparin in the reduction of incidence of VTE in hip replacement surgery patients. The primary endpoint occurred in 1.4% of apixaban patients compared to 3.9% in the enoxaparin arm; the secondary endpoint occurred in 0.5% of apixaban patients compared to 1.1% in patients treated with enoxaparin. In addition, the safety profiles were similar for both apixaban and enoxaparin [&lt;ulink linkID="1157641" linkType="Reference"&gt;1157641&lt;/ulink&gt;], [&lt;ulink linkID="1157738" linkType="Reference"&gt;1157738&lt;/ulink&gt;]. Similar results were published in December 2010 [&lt;ulink linkID="1164022" linkType="Reference"&gt;1164022&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Venous thromboembolism prevention in knee replacement&lt;/subtitle&gt;In June 2007, a phase III ADVANCE-2 (&lt;ulink linkID="7852" linkType="Protocol"&gt;NCT00452530&lt;/ulink&gt;; CV185-047, 2006-006896-19) trial began. In the randomized, double-blind, safety and efficacy study, 3054 patients received placebo plus apixaban (2.5 mg) twice daily or  enoxaparin (40 mg) once daily for 12 days. The primary endpoints included asymptomatic and symptomatic DVT, non-fatal PE and all-cause death. Secondary endpoints included proximal DVT, non-fatal PE, and  VTE-related death. The trial completed in January 2009  [&lt;ulink linkID="915530" linkType="Reference"&gt;915530&lt;/ulink&gt;]. In July 2009, data from the study were presented at the XXII ISTH Congress in Boston, MA. The primary endpoint was observed in 24.4% (243 out of 997) and 15.1% (147 of 976) of the evaluable patients randomized to receive enoxaparin and apixaban, respectively. The difference in the relative risk and absolute risk of DVT rates in the two treatment groups was less than 0.001 in each case. The differences in the observed clinically relevant bleeding (3.5% and 4.8% in the apixaban and enoxaparin arms, respectively), however, were not clinically significant. It was concluded that apixaban was more effective than enoxaparin for preventing DVT after total knee replacement [&lt;ulink linkID="1029223" linkType="Reference"&gt;1029223&lt;/ulink&gt;]. In August 2009, similar data were presented at the AIMECS 09 conference in Cairns, Australia [&lt;ulink linkID="1036418" linkType="Reference"&gt;1036418&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;]. In March 2010, similar data were published, which demonstrated that apixaban achieved a better antithrombotic effect compared to enoxaparin. The results showed that the secondary endpoint of major incidence of VTE occurred in 1.1% of apixaban patients compared to 2.2% for the enoxaparin group, which demonstrated a significant relative risk reduction of 50% for apixaban [&lt;ulink linkID="1079601" linkType="Reference"&gt;1079601&lt;/ulink&gt;], [&lt;ulink linkID="1079524" linkType="Reference"&gt;1079524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, a randomized, double-blind phase III trial (&lt;ulink linkID="5701" linkType="Protocol"&gt;NCT00371683&lt;/ulink&gt;, ADVANCE-1) to evaluate the use  of apixaban to prevent DVT and lung PE in  patients (n = 3202) undergoing elective knee replacement  surgery was initiated at sites across North America, South America, Europe, Israel and Australia. The study compared apixaban (2.5 mg twice daily) with enoxaparin (30 mg twice daily). The trial completed in May 2008. [&lt;ulink linkID="735400" linkType="Reference"&gt;735400&lt;/ulink&gt;], [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;].  In August 2008, an early results evaluation showed that apixaban had failed to meet the primary endpoint of non-inferiority to enoxaparin in the study. The primary endpoint was the composite of DVT, PE and any-cause death, and the rate was 9 and 8.9% for the two drugs, respectively, which was not significant. The rate for enoxaparin had been expected to be approximately 16%, based on previous studies. The major bleeding event rate was not significantly different for the two drugs, but the composite of non-major and major bleeding was 2.9% for apixaban compared with 4.3% for enoxaparin [&lt;ulink linkID="938327" linkType="Reference"&gt;938327&lt;/ulink&gt;]. Similar data were presented  at the 50th ASH meeting in San Francisco, CA in December 2008 [&lt;ulink linkID="966941" linkType="Reference"&gt;966941&lt;/ulink&gt;]. In July 2009, data presented at the XXII ISHT Congress in Boston, MA, noted that the  risk-benefit profiles of 2.5 mg of apixaban bid and 5 mg of apixaban qd were comparable with that of the current standards of care [&lt;ulink linkID="1029223" linkType="Reference"&gt;1029223&lt;/ulink&gt;]. In August 2009, similar data were presented at the AIMECS 09 conference in Cairns, Australia [&lt;ulink linkID="1036418" linkType="Reference"&gt;1036418&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2004, a phase II  trial (&lt;ulink linkID="4818" linkType="Protocol"&gt;NCT00097357&lt;/ulink&gt;; APROPOS; CV185-010) in subjects undergoing elective total knee replacement surgery was initiated in the US, Argentina, Australia, Canada, Denmark, Israel, Mexico, Poland and Puerto Rico. The  purpose of the study was to test the safety and efficacy of apixaban in preventing blood clots in the legs and lungs in patients following unilateral total knee replacement surgery. The study completed in December 2005 [&lt;ulink linkID="622602" linkType="Reference"&gt;622602&lt;/ulink&gt;], [&lt;ulink linkID="1222959" linkType="Reference"&gt;1222959&lt;/ulink&gt;]. In December 2006, clinical data on apixaban were presented at the 48th ASH meeting in Orlando, FL. In the randomized, double-blind study patients were treated with 5, 10 or 20 mg doses of the drug once a day, enoxaparin or warfarin. Treatment was post-surgery for 10 to 14 days. Of 1217 patients 856 were evaluable. The composite VTE plus all-cause death rate in the apixaban groups combined was significantly lower than in the enoxaparin and warfarin arms. A trend was seen in a dose-dependent decrease in VTE events plus all cause death rates for 2.5 (9.9%) and 5 mg (11.3%) doses of apixaban [&lt;ulink linkID="750221" linkType="Reference"&gt;750221&lt;/ulink&gt;]. In December 2006, data from the trial were presented. The results demonstrated that bid dosing with apixaban consistently produced lower rates of VTE/death compared with QD dosing or treatment with the standard of care (warfarin or enoxaparin), with comparable bleeding rates [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;]. In August 2009, similar data were presented at the AIMECS 09 conference in Cairns, Australia [&lt;ulink linkID="1036418" linkType="Reference"&gt;1036418&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Venous thromboembolism prevention in other indication&lt;/subtitle&gt;In January 2017, an open-label, randomized, parallel-assigned, prospective, multicenter, phase II trial (&lt;ulink linkID="281201" linkType="Protocol"&gt;NCT02981472&lt;/ulink&gt;; CV185-362; 2016-001247-39) to assess the safety and pharmacokinetics of apixaban compared to vitamin K antagonist, was initiated in children (expected n = 150) with congenital or acquired heart disease with a need for anticoagulation, in the US, Austria and Germany. At that time, the trial was also to begin in  Argentina, Australia, Brazil, Canada, France, Israel, Italy and Mexico, and  was  to complete in September 2020 [&lt;ulink linkID="1928509" linkType="Reference"&gt;1928509&lt;/ulink&gt;]. In February 2019, the trial was ongoing [&lt;ulink linkID="2123173" linkType="Reference"&gt;2123173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, a randomized, open-label, multi-center, phase III trial (&lt;ulink linkID="222656" linkType="Protocol"&gt;NCT02369653&lt;/ulink&gt;; CV185-155; 2014-000328-47) began in the US and Canada to assess apixaban for thromboembolism prevention versus no systemic anticoagulant prophylaxis during induction chemotherapy in pediatric patients (expected n = 500) with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B Cell) treated with asparaginase. The primary endpoint was a composite of adjudicated non-fatal DVT, PE, and cerebral venous sinus thrombosis and VTE-related death and adjudicated major bleeding at up to 1 month [&lt;ulink linkID="2152834" linkType="Reference"&gt;2152834&lt;/ulink&gt;]. In June 2015, clinical data about a multicentre, randomized, controlled, open-label, phase III trial (AESOP) in pediatric patients with acute lymphoblastic leukemia or lymphoma treated with L-asparaginase were presented at the XXV ISTH Congress in Toronto, Canada. Patients (expected n = 500) would be randomized to receive Apixaban or no anticoagulation during induction chemotherapy. At that time, the study was anticipated to require 3.5 years to complete patient accrual [&lt;ulink linkID="1681139" linkType="Reference"&gt;1681139&lt;/ulink&gt;]. In January 2019, further patients were expected to be enrolled in South Korea. At that time, the trial was expected to complete in May 2020 [&lt;ulink linkID="2152834" linkType="Reference"&gt;2152834&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In June 2007, a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (ADOPT) for medical VTE prevention was initiated (n = 6500) [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;];   by July 2008, the trial (&lt;ulink linkID="4889" linkType="Protocol"&gt;NCT00457002&lt;/ulink&gt;, CV185-036) was recruiting a further 1000 patients with acute medical illness. The trial compared apixaban (2.5 mg bid for 1 month) with 40 mg of &lt;ulink linkID="13928" linkType="Drug"&gt;enoxaparin&lt;/ulink&gt; daily for 6 to 14 days followed by placebo. The trial completed in May 2011 [&lt;ulink linkID="924956" linkType="Reference"&gt;924956&lt;/ulink&gt;].  In November 2011, data were presented at the American Heart Association Scientific Sessions in Orlando, FL. The trial did not meet the primary efficacy endpoint of superiority to enoxaparin for VTE and VTE-related death at day 30; the primary  endpoint occurred in 2.71 and 3.06% of patients in the apixaban and enoxaparin groups, respectively.  In addition, major bleeding was significantly higher in apixaban-treated patients (0.47%) compared with enoxaparin-treated patients (0.19%)  [&lt;ulink linkID="1239221" linkType="Reference"&gt;1239221&lt;/ulink&gt;], [&lt;ulink linkID="1239267" linkType="Reference"&gt;1239267&lt;/ulink&gt;], [&lt;ulink linkID="1239542" linkType="Reference"&gt;1239542&lt;/ulink&gt;], [&lt;ulink linkID="1241662" linkType="Reference"&gt;1241662&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006, a randomized, double-blind, placebo-controlled phase II  trial (&lt;ulink linkID="7886" linkType="Protocol"&gt;NCT00320255&lt;/ulink&gt;, CV185-027; ADVOCATE) for VTE prevention in patients undergoing treatment for advanced or metastatic cancer (n = 129) commenced. Patients were treated with apixaban (5 mg dq) or placebo for 12 weeks. The primary endpoint was the occurrence of a major bleeding (fatal or non-fatal) or a clinically relevant non-major bleeding event during treatment. The trial was completed in January 2009   [&lt;ulink linkID="924955" linkType="Reference"&gt;924955&lt;/ulink&gt;]. In July 2009, data from the study were presented at the XXII ISHT Congress in Boston, MA. The results showed that apixaban 5, 10 or 20 mg, given once daily for 12  weeks compared to placebo,  was well tolerated in patients (n = 85) with cancer on chemotherapy [&lt;ulink linkID="1043634" linkType="Reference"&gt;1043634&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Venous thromboembolism treatment&lt;/subtitle&gt;By April 2015, data were published and presented at the 79th Annual Scientific Meeting of the Japanese Circulation Society from a randomized, active-controlled, open-label, Japanese, phase III trial (AMPLIFY-J ) assessing the use of apixaban as monotherapy in patients with VTE and PE. The primary endpoint of the incidence of major or clinically important bleeding events compared with standard therapy (heparin and warfarin) had been met, with the same safety and efficacy demonstrated as in the global AMPLIFY study  [&lt;ulink linkID="1655435" linkType="Reference"&gt;1655435&lt;/ulink&gt;], [&lt;ulink linkID="1655513" linkType="Reference"&gt;1655513&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, pooled data were presented from the analysis of the AMPLIFY and AMPLIFY-EXT trials performed to evaluate the efficacy of apixaban, in avoiding clinical events compared to standard of care (SoC), for the initial and extended treatment and prevention of VTE,  at the AHA Scientific Sessions in Chicago, IL. For a cohort of 1000 patients, initial and extended treatment was projected to result in 63 fewer recurrent VTE events, 13 fewer major bleeds, and 28 fewer clinically relevant non-major bleeding bleeds, which resulted in 0.139 life years gained per patient [&lt;ulink linkID="1613863" linkType="Reference"&gt;1613863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, a multicenter, randomized, open-label, active-control, phase III (&lt;ulink linkID="106884" linkType="Protocol"&gt;NCT01780987&lt;/ulink&gt;; B0661024, CV185160, BMS) trial was initiated in patients (estimated n = 80) with VTE (DVT and PE) in Japan. At that time, the trial was to complete in June 2014. In February 2015, the trial was completed [&lt;ulink linkID="1413752" linkType="Reference"&gt;1413752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, the company initiated the 6-month, phase III, AMPLIFY trial (&lt;ulink linkID="9082" linkType="Protocol"&gt;NCT00643201&lt;/ulink&gt;; CV185-056, 2007-007867-25), as part of the EXPANSE program. In the safety and efficacy study, 4816 patients with acute DVT or PE received 10 mg of apixaban twice daily for 1 week, followed by 5 mg twice daily of apixaban for 6 months, or enoxaparin (1 mg/kg sc bid) plus daily warfarin. In May 2010, completion was expected in March 2013 [&lt;ulink linkID="915390" linkType="Reference"&gt;915390&lt;/ulink&gt;], [&lt;ulink linkID="924958" linkType="Reference"&gt;924958&lt;/ulink&gt;]. In June 2013, data from the 5395-patient trial were presented at the 24th Congress of the International Society on Thrombosis and Haemostasis in Amsterdam, the Netherlands. Apixaban was non-inferior to the current standard of care, enoxaparin plus warfarin, in the reduction of recurrent VTE and VTE-related death, the primary endpoint of the study. The composite outcome of major bleeding and clinically relevant non-major bleeding occurred in 4.3 and 9.7% of patients in the apixaban and current standard of care groups, respectively. Additionally, the rates of adverse events were similar between both treatment groups [&lt;ulink linkID="1446182" linkType="Reference"&gt;1446182&lt;/ulink&gt;], [&lt;ulink linkID="1446440" linkType="Reference"&gt;1446440&lt;/ulink&gt;]. In March 2014, further data, presented at the 63rd Annual Meeting of the American College of Cardiology in Washington DC, showed apixaban to significantly reduce all-cause hospitalizations compared to enoxaparin/warfarin therapy [&lt;ulink linkID="1542273" linkType="Reference"&gt;1542273&lt;/ulink&gt;]. In  September 2014, further data were presented at the ESC 2014 Annual Congress in Barcelona, Spain. The VTE recurrence was observed to be numerically higher in the cancer patients treated with apixaban (3.7%) when compared with enoxiparin/warfarin (5.4%). Also, a non-significant treatment interaction with respect to cancer status at baseline was observed. Apixaban-treated cancer patients had numerically lower rates of major bleeding and clinically relevant bleeding (2.3 and 5.0%, respectively) compared with enoxiparin/warfarin (12.0 and 22.1%) [&lt;ulink linkID="1588695" linkType="Reference"&gt;1588695&lt;/ulink&gt;].  Further data were presented at the same meeting. In the apixaban group, the incidence rate of major bleeding in those receiving concomitant antiplatelet therapy was found to be 3-fold higher than those who were not taking antiplatelet therapy; similarly in the conventional therapy group, patients receiving concomitant antiplatelet therapy had a 2.9-fold higher rate   [&lt;ulink linkID="1588662" linkType="Reference"&gt;1588662&lt;/ulink&gt;]. In December 2014, further clinical data were also presented at the 56th ASH Meeting in San Francisco, CA. Apixaban and warfarin had event rates of 1.0 and 2.0%, respectively at &amp;lt; 51.5% cTTR; 0.3 and 2.0%, respectively at 51.5 to 59.0% cTTR; 0.8 and 1.9%, respectively at 59.1 and 68.0% cTTR and 0.5 and 1.5%, respectively at &amp;gt; 68.0% cTTR for major bleeding [&lt;ulink linkID="1617700" linkType="Reference"&gt;1617700&lt;/ulink&gt;]. In June 2015, further post-hoc analysis  data were presented at the XXV ISTH Congress in Toronto, Canada. Overall, a trend was observed for less severe clinical presentation of major bleeding events in apixaban-treated patients when compared with low-molecular weight heparin/warfarin-treated patients and the clinical course was found to be similar for apixaban and warfarin associated major bleeding events [&lt;ulink linkID="1681268" linkType="Reference"&gt;1681268&lt;/ulink&gt;]. Further subgroup analysis data were also presented at the same conference showing that apixaban showed similar efficacy relative to conventional therapy in Asian and non-Asian patients [&lt;ulink linkID="1681288" linkType="Reference"&gt;1681288&lt;/ulink&gt;]. At the same conference, further clinical data were presented. Overall, the clinical presentation and subsequent extent of clinical care of clinically relevant non-major bleeding events associated with apixaban and with LMWH/warfarin were found to be comparable [&lt;ulink linkID="1681327" linkType="Reference"&gt;1681327&lt;/ulink&gt;]. In December 2015, further subanalysis data were published. The results of the subanalyses at each pre-specified time interval (7, 21, and 90 days) were consistent with the overall results of the AMPLIFY trial at 6 months, which demonstrated apixaban was non-inferior to conventional therapy in the primary efficacy endpoint of recurrent VTE and VTE-related death, and superiority, with significantly fewer major bleeding events, a 69% relative risk reduction, absolute risk reduction of 1.1 percentage points compared with conventional therapy. The respective, recurrent VTE and VTE-related death at 7, 21, and 90 days after starting treatment occurred in 18, 29 and 46 patients, and  23, 35 and 58 patients administered apixaban and conventional therapy, respectively [&lt;ulink linkID="1720503" linkType="Reference"&gt;1720503&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, the companies began the 12-month, phase III AMPLIFY-EXT trial (&lt;ulink linkID="8495" linkType="Protocol"&gt;NCT00633893&lt;/ulink&gt;, CV185-057, 2007-004953-27) as part of the phase III EXPANSE program. The study was to compare twice daily dosing of 2.5 or 5 mg of apixaban with placebo in 2430 patients with recurrent VTE, who had completed 6 to 12 months DVT or PE treatment [&lt;ulink linkID="915390" linkType="Reference"&gt;915390&lt;/ulink&gt;]. The study was scheduled for completion for January 2011; by September 2011, the completion date had been moved to December 2012  [&lt;ulink linkID="924959" linkType="Reference"&gt;924959&lt;/ulink&gt;]. In December 2012, data were presented from 2486 patients at the 54th ASH annual meeting in Atlanta, GA. Extended treatment with apixaban (2.5 and 5 mg bid) demonstrated superiority versus placebo in the reduction of the composite endpoint of symptomatic, recurrent VTE and death from any cause (11.6% in the placebo group, compared with 3.8 and 4.2% in the apixaban 2.5 and 5 mg groups, respectively). Similar data were also observed for the predefined secondary efficacy outcome of recurrent VTE and VTE-related death (8.8% in the placebo group, compared with 1.7% in both apixaban groups). Additionally, apixaban demonstrated lower all-cause mortality (placebo group 1.7%, compared with 0.8% and 0.5% in the 2.5 and 5 mg groups, respectively); however, the difference was not statistically significant. Across the trial, the rates of major bleeding were low and comparable (placebo 0.5%, 0.2% and 0.1% in the apixaban 2.5 and 5 mg groups, respectively). Rates of composite major bleeding or clinically relevant non-major bleeding were 2.7% in the placebo group, 3.2% in the apixaban 2.5 mg group, and 4.3% in the apixaban 5 mg group [&lt;ulink linkID="1348790" linkType="Reference"&gt;1348790&lt;/ulink&gt;]. In December 2013, further data were presented from 2482 patients at the 55th ASH Meeting in New Orleans, LA.  At 5 and 2.5 dose-levels, apixaban significantly reduced the risk of all-cause hospitalizations by 46 and 35%, respectively and prolonged the mean time to first hospitalization by 49 and 43 days, respectively; 17 and 26% of patients were hospitalized due to venous thromboembolism, respectively when compared with 51% of placebo recipients [&lt;ulink linkID="1503805" linkType="Reference"&gt;1503805&lt;/ulink&gt;]. In August 2014, further data were presented at the ESC 2014 Annual Congress in Barcelona, Spain. Baseline renal function impairment and PE were identified as significant predictors of all-cause hospitalization [&lt;ulink linkID="1589001" linkType="Reference"&gt;1589001&lt;/ulink&gt;], [&lt;ulink linkID="1588888" linkType="Reference"&gt;1588888&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2016, a phase I study (&lt;ulink linkID="272609" linkType="Protocol"&gt;NCT02912234&lt;/ulink&gt;; CV185-547 ) was to begin to assess the effect of &lt;ulink linkID="2829" linkType="Drug"&gt;clarithromycin&lt;/ulink&gt; on pharmacokinetics of apixaban in healthy subjects (expected n = 20). At that time, the study was expected to complete in October 2016. In October 2016, the study was initiated [&lt;ulink linkID="1801038" linkType="Reference"&gt;1801038&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, data from an open label, randomized, placebo-controlled, three-period crossover, phase I trial (&lt;ulink linkID="175663" linkType="Protocol"&gt;NCT02074358&lt;/ulink&gt;) which evaluated the effect of Cofact and Beriplex P/N on the pharmacodynamics and pharmacokinetics of apixaban in healthy subjects (n = 15), were presented at the 56th ASH Meeting in San Francisco, CA. Data demonstrated that administration of apixaban with and without Cofact and Beriplex treatment appeared to be safe and well tolerated [&lt;ulink linkID="1618663" linkType="Reference"&gt;1618663&lt;/ulink&gt;], [&lt;ulink linkID="1619296" linkType="Reference"&gt;1619296&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prevention of stroke in atrial fibrillation&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2017, a  multicenter, biomarker-driven, randomized, double-blind, active-control, phase III  trial (&lt;ulink linkID="302025" linkType="Protocol"&gt;NCT03192215&lt;/ulink&gt;; AAAR4607; ARCADIA) was to begin in the US, to examine supriority of  apixaban  in comparison to &lt;ulink linkID="51800" linkType="Drug"&gt;aspirin&lt;/ulink&gt; for the prevention of recurrent stroke in patients (expected n = 1100) with cryptogenic ischemic stroke and atrial cardiopathy in September 2017. In July 2017, the trial was to complete in April 2022 [&lt;ulink linkID="1945301" linkType="Reference"&gt;1945301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, an open-label, randomized, parallel-group phase IIIb study (&lt;ulink linkID="275565" linkType="Protocol"&gt;NCT02933697&lt;/ulink&gt;; AXADIA - AFNET 8) to assess the safety of apixaban versus vitamin-k antagonist, phenprocoumon, in patients (expected n = 222) with atrial fibrillation and end-stage kidney disease on chronic hemodialysis treatment, was scheduled to begin in January 2017 in Germany. At that time, completion of the study was expected in April 2019 [&lt;ulink linkID="1864170" linkType="Reference"&gt;1864170&lt;/ulink&gt;]. In July 2017, the trial was initiated [&lt;ulink linkID="1864170" linkType="Reference"&gt;1864170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, an open-label, prospective, randomized pilot,  phase II/III study (&lt;ulink linkID="270874" linkType="Protocol"&gt;NCT02889562&lt;/ulink&gt;; CV185-505 ) was planned to begin in October 2016, to assess the safety and efficacy of apixaban versus &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt; in  patients (expected n = 56) who developed atrial fibrillation after isolated coronary artery bypass grafting surgery. At that time, the study was expected to complete in December 2018. In September 2016, the study was initiated [&lt;ulink linkID="1795618" linkType="Reference"&gt;1795618&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, an open-label, randomized , active-control, parallel-group, pilot  phase III study (&lt;ulink linkID="215118" linkType="Protocol"&gt;NCT02283294&lt;/ulink&gt;; PRO00019754; AREST) was planned to initiate in the US to assess the safety and efficacy of the drug for the prevention of recurrent embolic stroke and hemorrhagic transformation in patients (expected n = 120 ) with atrial fibrillation in February 2015. At that time, the study was expected to complete in January 2018 [&lt;ulink linkID="1615046" linkType="Reference"&gt;1615046&lt;/ulink&gt;]. In October 2015, the trial was initiated  [&lt;ulink linkID="1615046" linkType="Reference"&gt;1615046&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, clinical data were presented at the 2012 ESC Congress in Munich, Germany. In an imputed-placebo, meta analysis of the ARISTOTLE and AVERROES studies found that apixaban reduced all-cause death by 33%, compared with placebo [&lt;ulink linkID="1317888" linkType="Reference"&gt;1317888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, a phase III study for thromboembolism in AF was ongoing in Japan [&lt;ulink linkID="1136903" linkType="Reference"&gt;1136903&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2007,  a second phase III stroke prevention in AF trial was initiated (AVERROES; &lt;ulink linkID="4979" linkType="Protocol"&gt;NCT00496769&lt;/ulink&gt;; CV185-048; CTR20132406), comparing apixaban to aspirin in patients (n = 6421, China n = 256). Patients were to receive apixaban (5 mg bid) or aspirin (81 to 324 mg qd) for up to 36 months or to the end of the study. The primary endpoint was the time (days) from first dose of study drug to first occurrence of unrefuted ischemic stroke, hemorrhagic stroke or systemic embolism. At that time, the trial was to  complete in August 2010; by August 2011, the expected completion date had changed to September 2012 [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;], [&lt;ulink linkID="924960" linkType="Reference"&gt;924960&lt;/ulink&gt;].   In February 2009, recruitment was started in China by BMS and Pfizer [&lt;ulink linkID="1703815" linkType="Reference"&gt;1703815&lt;/ulink&gt;]. In June 2010, the trial was stopped early after interim data demonstrated that apixaban had a more favorable safety profile and produced clinically significant reductions in the risk of stroke and systemic embolism in patients with atrial fibrillation (AF) who were  not suitable for vitamin K antagonist therapy, compared with aspirin [&lt;ulink linkID="1107594" linkType="Reference"&gt;1107594&lt;/ulink&gt;]. In August 2010, results from the study were presented at the European Society of Cardiology Congress in Stockholm, Sweden, showing that the annual rate of stroke and systemic embolism was 1.7% in the apixaban group compared with 3.9% in the aspirin group. There was no significant difference between the two arms in the incidence of major bleeding [&lt;ulink linkID="1136903" linkType="Reference"&gt;1136903&lt;/ulink&gt;]. The relative risk of a composite stroke or systemic embolism was reduced by 54% compared with aspirin [&lt;ulink linkID="1142172" linkType="Reference"&gt;1142172&lt;/ulink&gt;]. In February 2011, full results from the study were published. The relative risk of a composite stroke or systemic embolism following apixaban treatment was reduced by 55% compared with aspirin, with annual event rates of 1.6% for apixaban and 3.7% for aspirin in an intention-to-treat analysis. The relative risk of the secondary efficacy endpoint of the composite of stroke, systemic embolism, myocardial infarction or vascular death was reduced by 34%, with annual event rates of 4.2% for apixaban and 6.4% for aspirin. Cardiovascular hospitalization for apixaban was reduced compared with aspirin (12.6 versus 15.9%, respectively). Annual event rates for major bleeding were 1.4% for apixaban and 1.2% for aspirin, in an intention-to-treat analysis. Event rates in an on-treatment analysis were 1.4 and 0.9%, respectively. No evidence of hepatotoxicity associated with apixaban was observed in the study [&lt;ulink linkID="1167543" linkType="Reference"&gt;1167543&lt;/ulink&gt;], [&lt;ulink linkID="1167761" linkType="Reference"&gt;1167761&lt;/ulink&gt;]. In August 2011,  data from patients with chronic kidney disease (CKD) were presented at the ESC Congress 2011 in Paris, France. Compared with aspirin, apixaban  reduced the occurrence of the primary composite endpoint of  all strokes and systemic emboli by 68 and 43% in patients with stage III CKD (glomerular filtration rate = 30 to 59 ml/min) and patients with clearance =/&amp;gt; 60 ml/min, respectively. Major hemorrhagic events were similar for aspirin and apixaban, and there was no increase in major bleeding in patients with stage III CKD [&lt;ulink linkID="1218427" linkType="Reference"&gt;1218427&lt;/ulink&gt;]. Further data from a subanalysis from this trial on the effect of prior warfarin therapy were also presented at this meeting.  Across all subgroups of patients with prior warfarin therapy (total n = 2216), those who received apixaban had a 68% reduced risk of stroke or systemic embolism compared with those who received aspirin [&lt;ulink linkID="1219089" linkType="Reference"&gt;1219089&lt;/ulink&gt;]. By August 2015, recruitment had been finished. In June 2017, the trial completed [&lt;ulink linkID="1703816" linkType="Reference"&gt;1703816&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a worldwide, active-controlled, randomized, double-blind, parallel-assignment, phase III trial (&lt;ulink linkID="4965" linkType="Protocol"&gt;NCT00412984&lt;/ulink&gt;; CV185-030; ARISTOTLE) was initiated in patients (n = 18,201) with AF and risk factors for stroke in the US, South America, Europe, Australia, Canada, China, the Far East, India, Israel, Japan, Korea, Mexico, Puerto Rico, South Africa and Turkey. Patients were to receive  treatment qd for up to 40 months with either 5 mg  apixaban, 2.5 mg apixaban   plus placebo, or 2 mg &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt;  plus placebo. The primary endpoint was the time to  first occurrence of confirmed stroke or systemic embolism; secondary endpoints included all-cause death.  The study completed in May 2011 [&lt;ulink linkID="868428" linkType="Reference"&gt;868428&lt;/ulink&gt;],  [&lt;ulink linkID="857971" linkType="Reference"&gt;857971&lt;/ulink&gt;]. In June 2011, topline results were reported, which demonstrated that apixaban was non-inferior to warfarin on the combined outcome of stroke and systemic embolism, the primary endpoint. In addition, apixaban met secondary endpoints of superiority in efficacy and major bleeding compared with warfarin [&lt;ulink linkID="1202553" linkType="Reference"&gt;1202553&lt;/ulink&gt;]. In August 2011, further results were published and were presented at the ESC Congress 2011 in Paris, France. Treatment with apixaban versus warfarin significantly reduced the risk of stroke or systemic embolism, major bleeding and mortality by 21, 31 and 11%. In an intent-to-treat analysis, annual event rates of 1.27 and 1.60% for apixaban and warfarin, respectively, were observed. This was regardless of the quality of  warfarin treatment (time spent in warfarin INR therapeutic range) [&lt;ulink linkID="1218259" linkType="Reference"&gt;1218259&lt;/ulink&gt;], [&lt;ulink linkID="1218345" linkType="Reference"&gt;1218345&lt;/ulink&gt;], [&lt;ulink linkID="1218939" linkType="Reference"&gt;1218939&lt;/ulink&gt;], [&lt;ulink linkID="1220358" linkType="Reference"&gt;1220358&lt;/ulink&gt;], [&lt;ulink linkID="1221637" linkType="Reference"&gt;1221637&lt;/ulink&gt;], [&lt;ulink linkID="1218917" linkType="Reference"&gt;1218917&lt;/ulink&gt;]. In October 2011, similar data were presented at the Canadian Cardiovascular Congress 2011 in Vancouver, Canada [&lt;ulink linkID="1233653" linkType="Reference"&gt;1233653&lt;/ulink&gt;]. In March 2012, similar data were presented at the 61st ACC Meeting in Chicago, IL. Concomitant treatment with aspirin had no impact on the outcomes during apixaban therapy [&lt;ulink linkID="1275821" linkType="Reference"&gt;1275821&lt;/ulink&gt;]. In August 2012, further data were presented at the 2012 ESC Congress in Munich, Germany. Upon discontinuation of the study, patients were switched from apixaban to a vitamin K antagonist and followed for 30 days. There was an excess in thromboembolic and bleeding events, including stroke, in the apixaban arm upon discontinuation of the trial [&lt;ulink linkID="1317820" linkType="Reference"&gt;1317820&lt;/ulink&gt;]. Further data presented at this meeting showed that in patients requiring cardioversion, no patients experienced stroke or systemic embolism after 90 says and after 233 days respectively, stroke, systemic embolism, and myocardial infarction occurred in five patients assigned to apixaban, compared with six assigned to warfarin after 393 days [&lt;ulink linkID="1317822" linkType="Reference"&gt;1317822&lt;/ulink&gt;]. In October 2012, data from a subanalysis were published. Apixaban significantly reduced stroke or systemic embolism  irrespective of a patient's risk of stroke or bleeding. Additionally, patients who received apixaban had lower rates of major bleeding and intracranial bleeding compared with those who received warfarin, with no difference across CHADS2, CHA2DS2VASc, and HAS-BLED score categories [&lt;ulink linkID="1327710" linkType="Reference"&gt;1327710&lt;/ulink&gt;], [&lt;ulink linkID="1327798" linkType="Reference"&gt;1327798&lt;/ulink&gt;]. In November 2012, further data were presented at the AHA Scientific Sessions in Los Angeles, CA. Apixaban was associated with a reduced risk of intracranial hemorrhages and death within 30 days of a major intracranial hemorrhage compared with warfarin (hazard ratio = 0.42 and 0.50, respectively) [&lt;ulink linkID="1337790" linkType="Reference"&gt;1337790&lt;/ulink&gt;], [&lt;ulink linkID="1338337" linkType="Reference"&gt;1338337&lt;/ulink&gt;]. Further data presented at the same conference demonstrated that in patients with  (n = 6639) or without  (n = 11,545) prior coronary artery disease, the rates of stroke, major bleeding, myocardial infarction, all cause death and intracranial bleeding were lower in the apixaban group  than in the warfarin group  [&lt;ulink linkID="1337778" linkType="Reference"&gt;1337778&lt;/ulink&gt;]. Further data were presented at the same conference. In warfarin-naive and warfarin-experienced patients, the rates of stroke/systemic embolism, major bleeding and discontinuation  were lower in the apixaban group  when compared with the warfarin group [&lt;ulink linkID="1337779" linkType="Reference"&gt;1337779&lt;/ulink&gt;]. In May 2013, data were published from a prespecified subgroup analysis; reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with apixaban compared with warfarin were consistent across subgroups that were defined based on levels of INR control  [&lt;ulink linkID="1416412" linkType="Reference"&gt;1416412&lt;/ulink&gt;], [&lt;ulink linkID="1416159" linkType="Reference"&gt;1416159&lt;/ulink&gt;]. In September 2013, data from a post-hoc subanalysis  of nonvalvular AF patients who underwent a procedure were presented at the 2013 ESC Congress in Amsterdam, the Netherlands. In the 30-day period after a procedure, rates of stroke or systemic embolism, major bleeding, and all-cause death were comparable between the apixaban and warfarin treatment arms. In the apixaban group, the rates of clinical events in the 30-day period were similar regardless of whether treatment was stopped prior to the procedure or continued during the procedure; however, in the warfarin group,  a higher rate of major bleeding and death was observed in patients who continued to receive warfarin during the procedure compared with patients in whom warfarin was stopped prior to the procedure [&lt;ulink linkID="1471992" linkType="Reference"&gt;1471992&lt;/ulink&gt;]. At that time, further data from a post-hoc subanalysis comparing the safety and efficacy of apixaban to warfarin for the prevention of stroke or systemic embolism in non-valvular AF patients including those with or without other types of valvular heart disease (VHD) (n = 4,808) were also presented at the 2013 ESC Congress in Amsterdam, the Netherlands.  Lower rates of stroke or systemic embolism, major bleeding and all-cause mortality were observed in apixaban-treated patients compared with warfarin in patients with and without VHD. Data from this subanalysis were consistent with the overall results of the trial [&lt;ulink linkID="1472561" linkType="Reference"&gt;1472561&lt;/ulink&gt;]. In November 2013, further data were presented at the AHA Scientific Sessions in Dallas, TX. A lower risk of death and cardiovascular-related death was observed in women than in men. Efficacy and safety of apixaban were consistent irrespective of sex [&lt;ulink linkID="1496996" linkType="Reference"&gt;1496996&lt;/ulink&gt;]. In February 2014, data from a pre-specified subanalysis relating to patient age were published, showing consistent results across age groups with a greater absolute benefit in patients aged 75 years and older due to the higher incidence of cardiovascular events in older age [&lt;ulink linkID="1527977" linkType="Reference"&gt;1527977&lt;/ulink&gt;], [&lt;ulink linkID="1528062" linkType="Reference"&gt;1528062&lt;/ulink&gt;]. In March 2014, data from a pre-specified sub-analysis  were presented at the 63rd Annual Meeting of the American College of Cardiology in Washington DC. When evaluating blood pressure control as well as the treatment effect of apixaban versus warfarin on outcomes, there was a significantly higher risk of stroke or systemic embolism (approximately 50%)  associated with patients who had poor blood pressure control, independent of apixaban or warfarin therapy; however apixaban consistently reduced the risk of stroke or systemic embolism compared with warfarin in the overall population regardless of blood pressure control [&lt;ulink linkID="1540040" linkType="Reference"&gt;1540040&lt;/ulink&gt;]; data at the meeting also showed in patients with diabetes that there were lower rates of stroke and systemic embolism,  all-cause mortality and cardiovascular mortality; patients without diabetes had lower rates of bleeding with apixaban [&lt;ulink linkID="1542817" linkType="Reference"&gt;1542817&lt;/ulink&gt;]. In  April 2014, further data were presented at the 66th AAN Annual Meeting in Philadelphia, PA. In the apixaban group, 0.34 and 1.55% of stroke/embolic and major bleeding events were reported, respectively [&lt;ulink linkID="1544749" linkType="Reference"&gt;1544749&lt;/ulink&gt;]. In April 2014,  similar data were presented at the 66th AAN Annual Meeting in Philadelphia, PA [&lt;ulink linkID="1545199" linkType="Reference"&gt;1545199&lt;/ulink&gt;]. In September 2014, further data were presented at the ESC 2014 Annual Congress in Barcelona, Spain.  In the apixaban group, stroke/systemic embolism  events were reported by 0.62 and 1.07%/year of patients when compared with 1.03 and 1.89%/year of patients in the warfarin group with &amp;lt;/= 75.9 and &amp;gt; 75.9 pmol/l F1+2 levels, respectively. In the apixaban group, major/clinical significant non major bleed events were reported by 3.00 and 4.92%/year of patients when compared with 4.58 and 6.43%/year of patients in the warfarin group with &amp;lt;/= 401 and &amp;gt; 401 microg/l D-dimer levels, respectively [&lt;ulink linkID="1588943" linkType="Reference"&gt;1588943&lt;/ulink&gt;].  In November 2014, further data were presented at the AHA Scientific Sessions in Chicago, IL.  The hazard ratios for stroke/systemic embolic events (p = 0.68), hemorrhagic stroke (p = 0.87), death (p = 0.48) and major bleed (p = 0.32), the primary efficacy and safety outcomes, were 0.78, 0.50, 0.91 and 0.66, respectively in patients no bleeding history; the ratios were 0.86, 0.55, 0.82 and 0.78, respectively in patients with a bleeding history [&lt;ulink linkID="1613832" linkType="Reference"&gt;1613832&lt;/ulink&gt;]. In March 2015,  similar data were presented at the 64th American College of Cardiology Annual Scientific Sessions in San Diego, CA  [&lt;ulink linkID="1645821" linkType="Reference"&gt;1645821&lt;/ulink&gt;]. In August 2015, further clinical data were presented at the 2015 ESC Congress in London, UK.  Apixaban consistently associated with a lower risk of stroke, death and major bleeding, regardless of renal function overtime [&lt;ulink linkID="1690696" linkType="Reference"&gt;1690696&lt;/ulink&gt;].  At the same conference, further clinical data were also presented.  Data demonstrated that non-major bleeding was common, associated with adverse events, and less frequent with apixaban compared with warfarin [&lt;ulink linkID="1691083" linkType="Reference"&gt;1691083&lt;/ulink&gt;]. Further data from the trial were presented at the same conference. The relative risk reduction was 21 and 31% for stroke or systemic embolism (primary outcome) and ISTH-defined major bleeding, respectively. Time-in-therapeutic range was 66%. Data demonstrated that apixaban 5 mg bid was safer and more effective in patients with advanced age, low body weight or renal dysfunction compared with warfarin [&lt;ulink linkID="1690699" linkType="Reference"&gt;1690699&lt;/ulink&gt;].  In November 2015, further data were presented at the AHA's Scientific Sessions 2015 in Orlando, FL.   Apixaban was more effective in reducing stroke (p = 0.82), major bleeding (p = 0.02) and stroke/major bleeding/all-cause death (p = 0.10) when compared with warfarin [&lt;ulink linkID="1710610" linkType="Reference"&gt;1710610&lt;/ulink&gt;], [&lt;ulink linkID="1711335" linkType="Reference"&gt;1711335&lt;/ulink&gt;].  At the same conference, further data were presented.  Few major bleeding (p = 0.50), all-cause death (p = 0.88) and cardiovascular death (p = 0.53) were reported in both the groups [&lt;ulink linkID="1711976" linkType="Reference"&gt;1711976&lt;/ulink&gt;],  [&lt;ulink linkID="1711335" linkType="Reference"&gt;1711335&lt;/ulink&gt;]. At the same conference, further data were presented.  Patients with PAD had a non-significantly higher risk of stroke/systemic embolism when compared with patients without PAD. A significantly higher risk of all cause death and cardiovascular death was seen in patients with PAD an AF compared to those without PAD [&lt;ulink linkID="1713539" linkType="Reference"&gt;1713539&lt;/ulink&gt;],   [&lt;ulink linkID="1711335" linkType="Reference"&gt;1711335&lt;/ulink&gt;]. Similar data were presented at the same conference [&lt;ulink linkID="1710120" linkType="Reference"&gt;1710120&lt;/ulink&gt;], [&lt;ulink linkID="1711335" linkType="Reference"&gt;1711335&lt;/ulink&gt;]. In April 2016, further data from the analysis of ARISTOTLE study were presented at the 65th American College of Cardiology Annual Scientific Session and Expo in Chicago, IL. The effects of apixaban, compared with warfarin, on clinical outcomes were similar among patients with recent or remote onset AF. Clinical outcomes (event rate/100-patient-years) for apixaban versus warfarin were 1.23 versus 2.02, 3.31 versus 4.88, 0.53 versus 0.34, 2.08 versus 3.62, 3.97 versus 6.40 and 17.82 versus 25.71 for stroke or systemic embolism, all cause death, myocardial infarction, major bleeding, major or non-major clinically relevant bleeding and any bleeding with hazard ratios of 0.78, 1.11, 1.77, 0.73, 0.78 and 0.81, respectively [&lt;ulink linkID="1757287" linkType="Reference"&gt;1757287&lt;/ulink&gt;]. In August 2016, further data from this trial on the efficacy of apixaban versus warfarin in AF patients with cancer were presented at the 2016 ESC Congress in Rome, Italy. There were no significant differences in the event rates/100 person years of systemic embolism or stroke, or ISTH major bleeding  between patients with active cancer and those with no cancer [&lt;ulink linkID="1791879" linkType="Reference"&gt;1791879&lt;/ulink&gt;], [&lt;ulink linkID="1791931" linkType="Reference"&gt;1791931&lt;/ulink&gt;]. In March 2017, further clinical data were presented at the 66th American College of Cardiology Annual Scientific Session and Expo in Washington, DC. In patients on and off interacting medications, no significant differences were observed on the treatment effect of apixaban versus warfarin for outcomes including stroke or systemic embolism (p interaction = 0.79) or major bleeding (p interaction = 0.79) [&lt;ulink linkID="1917256" linkType="Reference"&gt;1917256&lt;/ulink&gt;]. In August 2017, further data were presented at the 2017 ESC congress in Barcelona, Spain. In patients with apolipoprotein A1 (ApoA1) biomarker level &amp;lt;/=0.94, &amp;gt;0.94 to 1.1, &amp;gt;1.1 to 1.3 and &amp;gt;1.3 unadjusted hazard ratios (HR) were 0.71, 0.64 and 0.55 (p &amp;lt;0.0001), respectively; adjusted risk factors HR were 0.75, 0.69 and 0.62 (p &amp;lt;0.0001), respectively; adjusted risk factors and biomarkers were 0.76, 0.72 and 0.66 (p = 0.0004), respectively. In patients with APoB biomarker level was unadjusted HR was 0.84, 0.80 and 0.84 (p &amp;lt;0.0001), respectively; adjusted risk factors HR were 0.89, 0.88 and 0.94 (p = 0.5224), respectively; adjusted risk factors and biomarkers were 0.89, 0.90 and 0.95 (p = 0.6132), respectively [&lt;ulink linkID="1956795" linkType="Reference"&gt;1956795&lt;/ulink&gt;].  In November 2017, further data were presented at the ASN's Kidney Week 2017 in New Orleans, LA.  Across categories of kidney function like CrCl&amp;lt; 30 versus &amp;gt;/= 30 ml/min, apixaban versus warfarin exhibited similar effect on stroke or systemic embolism over median follow up of 1.8 years. In apixaban and warfarin treatment group, on patients with CrCl &amp;lt; 30 ml/min, major bleeding was observed in 7 and 19 patients, respectively (hazard ratio = 0.34). Across CrCl categories, apixaban treatment reported similar safety results [&lt;ulink linkID="1977789" linkType="Reference"&gt;1977789&lt;/ulink&gt;]. In November 2017, further data of the association between multimorbidity (defined as &amp;gt;/= 3 chronic conditions) and the risk of thromboembolism/bleeding were presented at the 2017 AHA Scientific Sessions in Anaheim, CA. Across the range of multimorbidity (few, moderate and greatest), the safety and efficacy of apixaban and warfarin on stroke/systemic embolism, death, and major bleeding were consistent, with less bleeding with apixaban in all groups. Across all multimorbidity groups, patients randomized to apixaban had significantly lower intracranial hemorrhage (hazard ratio of 0.28 apixaban versus warfarin among 6+ comorbidities) [&lt;ulink linkID="1980695" linkType="Reference"&gt;1980695&lt;/ulink&gt;]. In March 2018, further data were presented at the 67th American College of Cardiology Annual Scientific Session and Expo in Orlando, FL. The efficacy and safety of apixaban versus warfarin appeared to be similar in patients with very high body weight (&amp;gt;/= 120 kg) when compared with those without very high body weight (&amp;lt; 120 kg). In apixaban- and warfarin-treated patients, the incidence rate of stroke/systemic embolism (primary efficacy endpoint) was 1.32 and 1.62 (body weight &amp;lt; 120 kg; p = 0.0268), and 0.40 and 1.18 (body weight &amp;gt;/= 120 kg; p = 0.0632), respectively; and major bleeding (primary safety endpoint) was 2.16 and 3.16 (body weight &amp;lt; 120 kg; p &amp;lt; 0.0001), and 1.67 and 2.00 (body weight &amp;gt;/= 120 kg; p = 0.6003), respectively [&lt;ulink linkID="2042790" linkType="Reference"&gt;2042790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2012, &lt;ulink linkID="1005894" linkType="Company"&gt;Portola&lt;/ulink&gt;, Pfizer and BMS planned to conduct a clinical proof-of-concept study to evaluate the safety of &lt;ulink linkID="60748" linkType="Drug"&gt;PRT-4445&lt;/ulink&gt; and its reverse of the anticoagulation activity of  apixaban and other factor Xa inhibitors, such as &lt;ulink linkID="44219" linkType="Drug"&gt;betrixaban&lt;/ulink&gt; [&lt;ulink linkID="1336913" linkType="Reference"&gt;1336913&lt;/ulink&gt;]. In December 2012, a phase II trial was initiated  and at that time, multiple cohorts  were planned for the trial  which was expected to be completed in 2013 [&lt;ulink linkID="1348963" linkType="Reference"&gt;1348963&lt;/ulink&gt;], [&lt;ulink linkID="1362792" linkType="Reference"&gt;1362792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2008, a randomized, partially-blind, open-label, active-controlled, phase IIb trial (&lt;ulink linkID="34660" linkType="Protocol"&gt;NCT00787150&lt;/ulink&gt;; B0661003; ARISTOTLE-J) was initiated in Japan in patients (n = 222) with nonvalvular AF at risk of stroke. The subjects were to receive  treatment for up to 12 weeks with apixaban (2.5 or 5 mg bid) or &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt;  (undisclosed dose, qd). The primary endpoint was the incidence of adjudicated major or clinically relevant non-major bleeding during treatment. The trial completed in September 2009 [&lt;ulink linkID="1222858" linkType="Reference"&gt;1222858&lt;/ulink&gt;]. In July 2011, results from the trial were published. The primary endpoint occurred in 1.4% of patients in each apixaban group compared with 5.3% in the warfarin arm. There were no strokes, systemic emboli, myocardial infarctions or deaths in either apixaban group, compared with 2 ischemic strokes and 1 subarachnoid hemorrhage, but no deaths, in the warfarin-treated group. Major and clinically relevant non-major bleeds occurred with higher frequency in the warfarin group compared with either apixaban group. Most adverse events were mild or moderate [&lt;ulink linkID="1222878" linkType="Reference"&gt;1222878&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prevention of cardiovascular events in  acute coronary syndrome&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2009, a randomized, double-blind, safety and efficacy phase III study (&lt;ulink linkID="43015" linkType="Protocol"&gt;NCT00831441&lt;/ulink&gt;; CV185-068; APPRAISE-2) was initiated. The study would determine if apixaban is superior to placebo for preventing      cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects (expected n = 10800) with     recent ACS. The study was to be completed In November 2011 [&lt;ulink linkID="1090839" linkType="Reference"&gt;1090839&lt;/ulink&gt;]; however, in November 2010, the trial was terminated on the recommendation of an independent Data Monitoring Committee (DMC), after the study revealed an increase in bleeding and no clinically meaningful reductions in ischemic events in patients treated with apixaban [&lt;ulink linkID="1149245" linkType="Reference"&gt;1149245&lt;/ulink&gt;]. In August 2012, clinical data were presented at the 2012 ESC Congress in Munich, Germany. Patients with a history of heart failure had a 2-fold increase of cardiovascular death or myocardial infarction and patients with acute heart failure had a higher risk of cardiovascular death and major bleeding [&lt;ulink linkID="1317537" linkType="Reference"&gt;1317537&lt;/ulink&gt;].   In November 2014, further data were presented at the AHA Scientific Sessions in Chicago, IL. The rates of cardiovascular (CV) death, myocardial infarction (MI) or ischemic stroke were 13.01 and 13.24 in the mono and dual therapy groups, respectively (p = 0.94). CV- (p = 0.95) and all-cause death (p = 0.57) rates were 6.29 and 9.73 and 4.38 and 6.34 in the mono and dual therapy groups, respectively [&lt;ulink linkID="1612038" linkType="Reference"&gt;1612038&lt;/ulink&gt;]. In March 2015, further clinical data were presented at the 64th American College of Cardiology Annual Scientific Sessions in San Diego, CA. Apixaban was associated with a numerically higher risk of CV death,  MI, or ischemic stroke when compared with placebo in patients with prior stroke but was not associated with worse clinical outcomes when compared with placebo in patients without prior stroke [&lt;ulink linkID="1647929" linkType="Reference"&gt;1647929&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2009, a phase II, placebo-controlled, randomized, double-blind, multicenter study (&lt;ulink linkID="47426" linkType="Protocol"&gt;NCT00852397&lt;/ulink&gt;; B0661004) was initiated in patients (n = 151) with recent ACS (&amp;lt;/= 7 days) in Japan. The primary outcome was the incidence of major bleeding and clinically relevant non-major bleeding evaluated by ISTH criteria during treatment with apixaban (2.5 or 5 mg bid). At that time, the study was expected to complete in December 2010. By March 2011, the trial had been terminated following  the data monitoring committee's recommendation after termination of the APPRAISE-2 trial [&lt;ulink linkID="1221218" linkType="Reference"&gt;1221218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, a  randomized,  double-blind, dose-ranging phase II trial (&lt;ulink linkID="5873" linkType="Protocol"&gt;NCT00313300&lt;/ulink&gt;; CV185-023; APPRAISE-1) was initiated in subjects (n = 1715) with ACS.  This was a multicenter study involving centers in North America, Western Europe and Russia. The primary endpoint was for major and clinically relevant non-major bleeding; the trial completed in May 2008 [&lt;ulink linkID="855304" linkType="Reference"&gt;855304&lt;/ulink&gt;]. In September 2008, data from the trial presented at the annual European Society of Cardiology meeting in Munich, Germany, indicated that apixaban plus aspirin, may reduce the risk of a secondary cardiovascular event  but increase bleeding. A total of 1715 patients received up to 165 mg of aspirin in combination with 2.5 or 10 mg bid of apixaban or 10 or 20 mg qd for 26 weeks. Administration of clopidogrel was at the physician's discretion. Results showed there was a non-significant relative risk reduction in cardiovascular events in the 2.5 and 10 mg apixaban groups (27 and 38%, respectively) compared with placebo. The incidence of ISTH-defined major bleeding plus clinically relevant non-major bleeding was 5.7% in 2.5 mg bid apixaban-treated patients, 7.9% for 10 mg qd patients and 3% for placebo-treated patients. The incidence of major bleeding was 0.8% with placebo, 1.6 and 1.9% with the 2.5 mg bid and 10 mg qd doses, respectively [&lt;ulink linkID="939750" linkType="Reference"&gt;939750&lt;/ulink&gt;]. In August 2009, data were presented from this trial at the AIMECS 09 conference in Cairns, Australia. Apixaban reduced the incidence of severe adverse events [&lt;ulink linkID="1036418" linkType="Reference"&gt;1036418&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In September 2016, &lt;ulink linkID="1042072" linkType="Company"&gt;Universitaire Ziekenhuizen Leuven&lt;/ulink&gt; initiated an  open-label, phase II study (&lt;ulink linkID="331618" linkType="Protocol"&gt;NCT03456648&lt;/ulink&gt;; S57150)  in Belgium in  patients (n = 24) treated with end-stage renal disease to assess the inter-dialytic pharmacokinetics, intra-dialytic pharmacokinetics and dose finding of the drug, in collaboration with BMS. The primary outcome was to measure anti-Xa activity. At that time, the trial was expected to complete in August  2018 [&lt;ulink linkID="2042697" linkType="Reference"&gt;2042697&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2017, clinical data from four  real-world, US claims database retrospective studies were presented at the 2017 ESC congress in Barcelona, Spain. A total of 31,827 patients received standard-dose apixaban-warfarin and 6,600 patients received lower-dose apixaban-warfarin matched pairs with a mean follow-up of 6 months.  Overall, compared to standard-dose (5 mg) apixaban patients, lower-dose (2.5 mg bid ) apixaban patients had higher CHA2DS2-VASc and HAS-BLED scores, and were more than twice as likely to have renal disease . Compared to matched warfarin patients, standard-dose and lower-dose apixaban patients were associated with lower risks of stroke/systemic embolism and major bleeding  [&lt;ulink linkID="1956794" linkType="Reference"&gt;1956794&lt;/ulink&gt;], [&lt;ulink linkID="1956430" linkType="Reference"&gt;1956430&lt;/ulink&gt;]. Further data were presented at the same conference. Compared to warfarin initiators, apixaban initiators exhibited a significantly lower risk of stroke/systemic embolism (SE) and major bleeding (hazard ratio = 0.67 and 0.60, respectively; p &amp;lt; 0.001). Also, when compared to warfarin treatment, apixaban treated patients exhibited consistent results of lower risk of stroke/SE and major bleeding associated to treatment in an analyses stratified by age, gender, CHADS2 score, CHA2 DS2 -VASc score, HAS-BLED score, congestive heart failure, coronary artery disease, peripheral artery disease, renal disease, prior stroke/SE, and diabetes [&lt;ulink linkID="1956925" linkType="Reference"&gt;1956925&lt;/ulink&gt;], [&lt;ulink linkID="1956430" linkType="Reference"&gt;1956430&lt;/ulink&gt;], [&lt;ulink linkID="1956621" linkType="Reference"&gt;1956621&lt;/ulink&gt;]. In November 2017, further data were presented at the 2017 AHA Scientific Sessions in Anaheim, CA. Within one year of treatment initiation, apixaban treated patients had similar rate of stroke/SE when compared with dabigatran and rivaroxaban (HR values of 0.75 and 1.05, respectively; p = 0.086 and 0.585, respectively). Significantly lower rate of major bleeding was observed in apixaban treated patients within one year of treatment initiation when compared with warfarin and rivaroxaban (HR of 0.63 and 0.62, respectively; p &amp;lt; 0.001 for both). A similar rate of major bleeding was observed with apixaban treatment when compared with dabigatran treated patients (HR = 0.83; p = 0.107) [&lt;ulink linkID="1980739" linkType="Reference"&gt;1980739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  November 2016, results from a nationwide, observational cohort study evaluating the safety and efficacy of non-vitamin K antagonist oral anticoagulants including apixaban, dabigatran and rivaroxaban compared with &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt; in patients with AF were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. Out of 55,644 patients included from three nationwide registries, 4400, 8875, 3476 and 38,893 patients were treated with apixaban, dabigatran, rivaroxaban and warfarin, respectively. Incidence of ischemic stroke/systemic embolism was 4.7, 3.3, 3.5 and 3.7% with apixaban, dabigatran, rivaroxaban and warfarin, respectively (incidence of bleeding was 5.4, 4.3, 5.8 and 5.4%, respectively) [&lt;ulink linkID="1872163" linkType="Reference"&gt;1872163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. Patients who were admitted to the hospital received warfarin, &lt;ulink linkID="32677" linkType="Drug"&gt;rivaroxaban&lt;/ulink&gt;, apixaban, &lt;ulink linkID="24343" linkType="Drug"&gt;dabigatran&lt;/ulink&gt; or &lt;ulink linkID="51255" linkType="Drug"&gt;edoxaban&lt;/ulink&gt; a day before or on the day admitted to the hospital. The median length of stay in the hospital was 4 days [&lt;ulink linkID="1872140" linkType="Reference"&gt;1872140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, data from a real-world, retrospective cohort analysis which compared the risk of major bleeding episodes overall and stratified by congestive heart failure (CHA)2 diabetes, stroke (DS)2-vascular disease (VASc) scores in non-valvular atrial fibrillation patients (n = 36,427) treated with apixaban and warfarin, were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. A significantly lower risk of major bleeding was reported in apixaban- versus warfarin-treated patients in the overall, low, and high risk populations after adjusted for baseline characteristics and stratified by stroke risk with an adjusted hazard ratio of 0.61, 0.37, and 0.63, respectively [&lt;ulink linkID="1872111" linkType="Reference"&gt;1872111&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, data from a retrospective analysis of Humedica de-identified electronic health records real-world study which performed to evaluate the bleeding risk among elderly and overall non-valvular atrial fibrillation patients (n = 71,909) prescribed oral anticoagulants, apixaban, dabigatran, rivaroxaban and warfarin were presented at the 2016 ESC Congress in Rome, Italy. In elderly patients (n = 36,652) treated with apixaban, rivaroxaban and dabigatran, adjusted hazard ratios (HR; versus warfarin) for risk of bleeding was 0.881, 1.161 and 0.829, respectively; while adjusted HR (versus warfarin) was 0.847, 1.088 and 0.721 in overall patients treated with apixaban, rivaroxaban and dabigatran, respectively [&lt;ulink linkID="1792352" linkType="Reference"&gt;1792352&lt;/ulink&gt;]. In November 2016, further clinical data from 13,103 patients were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. After adjusting for baseline characteristics, risk of major bleeding was significantly lower in patients receiving apixaban-treated patients than warfarin treated patients (hazard ratio [HR] =0.62). Non-significant numerically lower risk of major bleeding was observed in dabigatran-treated patients (HR = 0.81) and rivaroxaban (HR=1.05) patients had a similar risk of major bleeding compared to warfarin patients [&lt;ulink linkID="1872027" linkType="Reference"&gt;1872027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, an open-label, multicenter, randomized, prospective, interventional, parallel assignment phase IIIb trial (&lt;ulink linkID="251967" linkType="Protocol"&gt;NCT02664649&lt;/ulink&gt;; P141102  2015-001676-21, ATLANTIS) was planned in France in patients (expected n = 1509) who had undergone a successful Transcatheter Aortic Valve Replacement procedure to demonstrate superiority of a strategy of anticoagulation with apixaban compared to the current standard of care.  The trial began in February 2017 and at that time was expected  to complete in April 2019 [&lt;ulink linkID="1733671" linkType="Reference"&gt;1733671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presented from an open-label, randomized, three-period, three-treatment, cross-over study in 33 healthy subjects at the 116th ASCPT Annual Meeting in New Orleans, LA. Subjects received 10 mg apixaban tablets (2 x 5 mg whole tablets, 2 x 5 mg tablets crushed and suspended in 30 ml water or 2 x 5 mg tablets crushed and mixed with 30 g applesauce) on day 1, followed by alternate treatments on days 5 and 9 with 3-day washout periods. Apixaban bioavailability was comparable between whole tablets and crushed tablets suspended in water, while it was 20% lower when crushed tablets suspended in applesauce. Apixaban was safe and well tolerated [&lt;ulink linkID="1638451" linkType="Reference"&gt;1638451&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2014, data presented at the 2014 ACCP Annual Meeting in Atlanta, GA, showed that in healthy subjects no pharmacokinetic or pharmacodynamic interaction was seen with combining apixaban with aspirin or clopidogrel [&lt;ulink linkID="1596790" linkType="Reference"&gt;1596790&lt;/ulink&gt;]. Further data presented at the meeting showed similar results for co-administration with prasugrel in a group of healthy subjects [&lt;ulink linkID="1597148" linkType="Reference"&gt;1597148&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, a multinational, non-randomized, open-label, parallel-group, phase I study (&lt;ulink linkID="70039" linkType="Protocol"&gt;NCT01195727&lt;/ulink&gt;; CV185-079) began to assess the pharmacokinetics and safety of apixaban in pediatric patients (n = 60) with a central venous catheter. The trial was expected to complete in January 2012 [&lt;ulink linkID="1223846" linkType="Reference"&gt;1223846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a non-randomized, open-label, parallel-group, phase I trial (&lt;ulink linkID="76706" linkType="Protocol"&gt;NCT01340586&lt;/ulink&gt;; CV185-087) began in the US to assess the pharmacokinetics and safety of apixaban (5 mg single dose) in subjects (n = 16) with normal renal function or with end-stage renal disease maintained by  hemodialysis. The study was expected to complete in September 2011 [&lt;ulink linkID="1223845" linkType="Reference"&gt;1223845&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2009, phase I data were presented at the AIMECS 09 conference in Cairns, Australia.  In healthy volunteers, factors including race, age and disease severity did not have an impact on AUC [&lt;ulink linkID="1036418" linkType="Reference"&gt;1036418&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By November 2004, the company had undisclosed follow-on compounds to &lt;ulink linkID="32750" linkType="Drug"&gt;razaxaban&lt;/ulink&gt;  in phase I and II trials [&lt;ulink linkID="572056" linkType="Reference"&gt;572056&lt;/ulink&gt;]. In March 2005, one compound had a more favorable profile to razaxaban, and had superseded razaxaban, being  in phase II trials [&lt;ulink linkID="591298" linkType="Reference"&gt;591298&lt;/ulink&gt;]; in August 2005, this compound  was revealed   to be  apixaban [&lt;ulink linkID="618892" linkType="Reference"&gt;618892&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2012, data from an in vitro study investigating the reversal of apixaban were presented in the American Heart Association's Emerging Science Series webinar. Apixaban (200 ng/ml) was added to blood from healthy donors and the blood clotting response to prothrombin complex concentrates (PCC), activated prothrombin complex concentrates (aPCC) and recombinant Factor VII (rFVIIa) was assessed. PCC and aPCC were more effective compared with rFVIIa for restoring thrombin generation, although rFVIIa resulted in the fastest production of a compact blood clot [&lt;ulink linkID="1302930" linkType="Reference"&gt;1302930&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2009, preclinical data were presented at the AIMECS 09 conference in Cairns, Australia. The compound had an oral bioavailability of 50%, no food effect and a half-life of 12 h [&lt;ulink linkID="1036418" linkType="Reference"&gt;1036418&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008,  data were presented at the 50th ASH meeting in San Francisco, CA. In a rabbit model of venous thrombosis, apixaban demonstrated a similar efficacy and safety profile to &lt;ulink linkID="32677" linkType="Drug"&gt;rivaroxaban&lt;/ulink&gt;, while &lt;ulink linkID="24343" linkType="Drug"&gt;dabigatran&lt;/ulink&gt; and &lt;ulink linkID="3284" linkType="Drug"&gt;lepirudin&lt;/ulink&gt; demonstrated increased bleeding times compared to these drugs [&lt;ulink linkID="966276" linkType="Reference"&gt;966276&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007,  data were presented at the 49th ASH meeting in Atlanta, GA. Apixaban showed efficacy and safety equivalent to &lt;ulink linkID="4476" linkType="Drug"&gt;fondaparinux&lt;/ulink&gt; in rabbit arteriovenous shunt, venous thrombosis  and cuticle bleeding time models [&lt;ulink linkID="857919" linkType="Reference"&gt;857919&lt;/ulink&gt;]. It also showed efficacy in rat thrombosis models [&lt;ulink linkID="859902" linkType="Reference"&gt;859902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006,  data  were presented at the 48th ASH meeting in Orlando, FL. Apixaban demonstrated favorable pharmacokinetic and metabolic characteristics in several animal models. The drug had a mean oral bioavailability of 51, 88 and 34% in chimpanzees, dogs and rats, respectively. The in vitro metabolic clearance was low with a lack of significant metabolism in human liver microsomes and hepatocytes and in chimpanzee and dog live microsomes and multiple elimination pathways were observed. The drug did not inhibit CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4 activities in cDNA-expressed enzyme systems and human liver microsomes, or 1A2, 2B6 and CYP3A4 in human hepatocytes. Venous thrombus was induced in rabbits by placing threads in the vena cava and bleeding was induced by the incision of cuticles. Apixaban at 0.1 to 3 mg/kg doses was then infused iv over 60 min or rabbits were treated with  oral warfarin administered for 4 days before the start of the study. Both drugs dose-dependently inhibited the formation of venous thrombi.   The IC50 value for apixaban was 160 microg. Both drugs also increased prothrombin time [&lt;ulink linkID="746824" linkType="Reference"&gt;746824&lt;/ulink&gt;], [&lt;ulink linkID="746803" linkType="Reference"&gt;746803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005,  data were presented at the 230th ACS meeting in Washington DC. The compound had a Ki value of 0.08 nM against FXa. At 0.2 mg/kg po, efficacy of the compound was  observed in a rabbit arteriovenous shunt model, with no cytotoxicity observed. It  showed no  interaction with cytochrome p450 or HERG (IC50 &amp;gt; 25 microM) and was negative in Ames mutagenicity assays  [&lt;ulink linkID="618892" linkType="Reference"&gt;618892&lt;/ulink&gt;], [&lt;ulink linkID="622712" linkType="Reference"&gt;622712&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In April 2018, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the treatment of venous thromboembolism [&lt;ulink linkID="2031838" linkType="Reference"&gt;2031838&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;December 2008, the EMA's Pediatric Committee adopted a positive opinion on a  pediatric investigation plan (PIP) for the product for cardiovascular disease [&lt;ulink linkID="971771" linkType="Reference"&gt;971771&lt;/ulink&gt;]. In April 2015, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for apixaban for the prevention of venous and arterial thromboembolism [&lt;ulink linkID="1655017" linkType="Reference"&gt;1655017&lt;/ulink&gt;]. In August 2016, the EMA's Pediatric Committee adopted positive opinion for modifications of an agreed PIP for apixaban in the prevention of venous and arterial thromboembolism [&lt;ulink linkID="1793043" linkType="Reference"&gt;1793043&lt;/ulink&gt;].  In June 2017, EMA's Pediatric Committee adopted a positive opinion on further modifications to the PIP for the prevention of arterial thromboembolism and prevention of venous thromboembolism [&lt;ulink linkID="1945191" linkType="Reference"&gt;1945191&lt;/ulink&gt;].  In April 2018, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the prevention of arterial thromboembolism and prevention of venous thromboembolism [&lt;ulink linkID="2031838" linkType="Reference"&gt;2031838&lt;/ulink&gt;]&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Eduard Shantsila &amp;amp; Gregory YH Lip, City Hospital, University Department of Medicine, Birmingham, UK&lt;/para&gt;&lt;para&gt;Submission date: 25 June 2008&lt;br/&gt;Publication date: 01 September 2008&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;The oral direct factor Xa inhibitor apixaban is being developed &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb Co&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="18767"&gt;Pfizer Inc&lt;/ulink&gt; for the prevention and treatment of arterial and venous thrombosis. Apixaban was safe and demonstrated antithrombotic effects in preclinical thrombosis models and phase II trials in patients with deep vein thrombosis (DVT) or those undergoing knee replacement surgery. It has a predictable dose-response relationship, does not require intensive monitoring, and may be safely co-administered with antiplatelet drugs and a number of other anticoagulants. Several phase II/III trials are ongoing. These trials are designed to evaluate the effectiveness and safety of apixaban in the treatment of DVT and pulmonary embolism in patients with recent acute coronary syndrome, the prevention of stroke or systemic embolism in patients with atrial fibrillation and the prevention of thrombosis-related events in patients undergoing knee or hip replacement surgery and in patients with acute medical illness. In the phase III ADVANCE-1 trial, preliminary results indicated that apixaban met the primary efficacy endpoint with a similar rate as enoxaparin sodium; further knee surgery trials were subsequently being considered by the companies. The authors conclude that apixaban having a wide therapeutic index and a lack of known inter-drug interactions would be advantageous over approved and novel anticoagulant drug.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Since the discovery of heparin in 1916 [&lt;ulink linkType="Reference" linkID="925903"&gt;925903&lt;/ulink&gt;], the use of anticoagulants has greatly advanced the prevention and treatment of life-threatening thromboembolic events. In accordance with current guidelines, anticoagulants are widely used in clinical practice.&lt;/para&gt;&lt;para&gt;Venous thromboembolism (VTE), manifesting as deep vein thrombosis (DVT) or pulmonary embolism (PE), affects approximately 900,000 individuals each year in the US and 1,130,000 individuals, in Western European countries; PE causes 670,000 fatalities annually in the US and Western Europe [&lt;ulink linkType="Reference" linkID="925907"&gt;925907&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="925912"&gt;925912&lt;/ulink&gt;]. In addition, DVT can lead to post-thrombotic syndrome (characterized by pain, swelling and ulceration) in 20 to 50% of patients within one to two years [&lt;ulink linkType="Reference" linkID="924814"&gt;924814&lt;/ulink&gt;]. Anticoagulant therapy remains the cornerstone of prophylaxis and treatment for VTE. It is used as prophylaxis in patients at high risk (eg, during lower limb orthopedic or major general surgical procedures) of VTE, or as treatment following a confirmed case of DVT or PE [&lt;ulink linkType="Reference" linkID="925914"&gt;925914&lt;/ulink&gt;]. The other application commonly requiring anticoagulant therapy is atrial fibrillation (AF), which is the most widespread sustained cardiac rhythm disorder and affects approximately 5% of individuals over 65 years of age and nearly 10% of those aged over 80 [&lt;ulink linkType="Reference" linkID="924950"&gt;924950&lt;/ulink&gt;]. AF is also associated with a 5-fold increased risk of embolic stroke. As many as 15% of all strokes are directly attributable to the arrhythmia, with an associated increase in mortality and morbidity [&lt;ulink linkType="Reference" linkID="924848"&gt;924848&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924865"&gt;924865&lt;/ulink&gt;]. One of the main objectives of long-term anticoagulant treatment for patients with AF is to prevent stroke and systemic thromboembolism. The vitamin K antagonists (VKAs; eg, &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;) were – at the time of publication – the only oral anticoagulant drugs recommended for the prevention of stroke in patients with a moderate-to-high risk of stroke, which includes the majority of patients (~ 75%) with AF [&lt;ulink linkType="Reference" linkID="924879"&gt;924879&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="44375"&gt;Warfarin&lt;/ulink&gt; is a particularly effective thromboprophylactic agent and reduces the risk of AF-related stroke and systemic thromboembolism by approximately two-thirds [&lt;ulink linkType="Reference" linkID="924897"&gt;924897&lt;/ulink&gt;]. Anticoagulant therapy may also be recommended for the prevention of recurrent myocardial infarction in patients with acute coronary syndromes (ACSs) [&lt;ulink linkType="Reference" linkID="924938"&gt;924938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Several anticoagulant drugs are currently used in clinical settings and immediate anticoagulation can now be achieved with parenteral anticoagulants, such as heparin (whether low-molecular-weight heparins [LMWHs], or unfractionated heparin [UFH]), or the parenteral indirect Factor Xa inhibitor &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; (a synthetic pentasaccharide) [&lt;ulink linkType="Reference" linkID="926770"&gt;926770&lt;/ulink&gt;]. Factor Xa is a trypsin-like serine protease that is crucial for the conversion of prothrombin to thrombin, the inhibition of which prevents coagulation. Compared with UFH, LMWH and &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; have better bioavailability after subcutaneous injection, a longer half-life and more predictable anticoagulant response, and avoid the need to intensely monitor the activated partial thromboplastin time (APTT) [&lt;ulink linkType="Reference" linkID="926776"&gt;926776&lt;/ulink&gt;]. However, because LMWH and &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; are available by parenteral injection only, these agents remain inconvenient and costly for long-term use, particularly outside the hospital setting.&lt;/para&gt;&lt;para&gt;Chronic anticoagulant therapy usually involves the administration of an oral agent. Currently, the only orally available anticoagulants are the VKAs, such as &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;. However, the use of &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; can be problematic, as it has slow onset (and offset) of action, requiring overlap with a parenteral anticoagulant for at least 5 days during the initiation phase. &lt;ulink linkType="Drug" linkID="44375"&gt;Warfarin&lt;/ulink&gt; has a narrow therapeutic window and subtherapeutic anticoagulationmay result in stroke or PE, whereas excessive anticoagulation increases the risk of bleeding [&lt;ulink linkType="Reference" linkID="924939"&gt;924939&lt;/ulink&gt;]. The therapeutic dose of &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; also varies from patient to patient, reflecting numerous food and drug interactions, as well as genetic polymorphism in the enzymes involved in &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; metabolism, making the pharmacokinetics of &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; unpredictable [&lt;ulink linkType="Reference" linkID="814315"&gt;814315&lt;/ulink&gt;]. These limitations necessitate frequent and inconvenient therapeutic monitoring and dose adjustment to ensure that anticoagulant effects remain within the therapeutic range. As a result, there is a high rate of patient dissatisfaction with &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; and a compliance rate of &amp;lt; 50% has been observed in the community setting [&lt;ulink linkType="Reference" linkID="814315"&gt;814315&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924951"&gt;924951&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The limitations of currently available anticoagulants, as well as the unmet clinical requirements of a large commercial market, have motivated the pharmaceutical industry to invest in novel anticoagulant drugs. Until recently, most anticoagulants were proteins extracted from hemophagic animals and insects (eg, recombinant hirudin [&lt;ulink linkType="Reference" linkID="925946"&gt;925946&lt;/ulink&gt;]) or from snake venoms (eg, Factor IX binding protein from Trimeresurus flavoviridis [&lt;ulink linkType="Reference" linkID="925916"&gt;925916&lt;/ulink&gt;]). However, advances in structure-based molecular design have facilitated the creation of novel oral small-molecule anticoagulants that specifically inhibit the activity of coagulation enzymes [&lt;ulink linkType="Reference" linkID="924357"&gt;924357&lt;/ulink&gt;]. Based on these technological advances, it is now possible to modulate the coagulation process at almost every step.&lt;/para&gt;&lt;para&gt;As thrombin and Factor Xa are the final elements of the coagulation cascade, it is not surprising that the number of promising compounds that target these enzymes has increased during the last decade. Among the oral anticoagulant drugs at various clinical stages of development are the oral direct thrombin inhibitors (eg, &lt;ulink linkType="Company" linkID="14881"&gt;Boehringer Ingelheim Corp&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt;, which was approved in the EU for post-surgical VTE in March 2008 [&lt;ulink linkType="Reference" linkID="889574"&gt;889574&lt;/ulink&gt;] and was launched by August 2008 [&lt;ulink linkType="Reference" linkID="926782"&gt;926782&lt;/ulink&gt;]; and &lt;ulink linkType="Drug" linkID="28951"&gt;AZD-0837&lt;/ulink&gt;, in phase III clinical development by &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca plc&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="930119"&gt;930119&lt;/ulink&gt;]), which bind to thrombin and block its interaction with substrates [&lt;ulink linkType="Reference" linkID="926780"&gt;926780&lt;/ulink&gt;]. A second group consists of the indirect oral Factor Xa inhibitors that block Factor Xa via antithrombin III (eg, &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="24026"&gt;idraparinux sodium&lt;/ulink&gt;, which is undergoing phase III clinical development by &lt;ulink linkType="Company" linkID="1009547"&gt;sanofi-aventis&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="873069"&gt;873069&lt;/ulink&gt;]). A third group of oral anticoagulant drugs is the direct oral inhibitors that bind to the active site of Factor Xa and block the interaction of Factor Xa with its substrates (eg, &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; by &lt;ulink linkType="Company" linkID="14455"&gt;Bayer AG&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="25863"&gt;Ortho-McNeil Pharmaceutical Inc&lt;/ulink&gt;, currently at the pre-registration stage [&lt;ulink linkType="Reference" linkID="846362"&gt;846362&lt;/ulink&gt;]; &lt;ulink linkType="Drug" linkID="47617"&gt;YM-150&lt;/ulink&gt; by &lt;ulink linkType="Company" linkID="1013295"&gt;Astellas Pharma Inc&lt;/ulink&gt; undergoing phase II clinical trials [&lt;ulink linkType="Reference" linkID="778698"&gt;778698&lt;/ulink&gt;]; and &lt;ulink linkType="Drug" linkID="51255"&gt;DU-176b&lt;/ulink&gt; by &lt;ulink linkType="Company" linkID="1020322"&gt;Daiichi Sankyo Inc&lt;/ulink&gt; undergoing phase II clinical development [&lt;ulink linkType="Reference" linkID="815272"&gt;815272&lt;/ulink&gt;]).&lt;/para&gt;&lt;para&gt;Also in this third group is apixaban, which is being developed by &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb Co&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="18767"&gt;Pfizer Inc&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="787553"&gt;787553&lt;/ulink&gt;]. At the time of publication, apixaban was undergoing phase II and III clinical trials in a variety of thromboembolic disorders [&lt;ulink linkType="Reference" linkID="855304"&gt;855304&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="868428"&gt;868428&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="915530"&gt;915530&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="915533"&gt;915533&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924955"&gt;924955&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924956"&gt;924956&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924958"&gt;924958&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924959"&gt;924959&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="924960"&gt;924960&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="926784"&gt;926784&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The discovery of the pyrazole scaffold was an important step toward the synthesis of a new family of molecules with the ability to inhibit the activity of Factor Xa [&lt;ulink linkType="Reference" linkID="398701"&gt;398701&lt;/ulink&gt;]. One such compound was &lt;ulink linkType="Drug" linkID="32750"&gt;razaxaban&lt;/ulink&gt;, the first direct Factor Xa inhibitor to be advanced into clinical development by &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; on the basis of high selectivity, efficacy and the possibility of oral administration [&lt;ulink linkType="Reference" linkID="516018"&gt;516018&lt;/ulink&gt;]. However, the consequent synthesis of a bicyclic tetrahydropyrazolopyridinone scaffold to eliminate in vivo hydrolysis of the carboxamido group and optimization of P1 moieties and C­3-substituents on the pyrazole ring [&lt;ulink linkType="Reference" linkID="852586"&gt;852586&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="925016"&gt;925016&lt;/ulink&gt;] resulted in the discovery of apixaban, the follow-on molecule to &lt;ulink linkType="Drug" linkID="32750"&gt;razaxaban&lt;/ulink&gt; with an improved pharmacokinetic profile [&lt;ulink linkType="Reference" linkID="618892"&gt;618892&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="852586"&gt;852586&lt;/ulink&gt;]. By March 2005, &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; had discontinued &lt;ulink linkType="Drug" linkID="32750"&gt;razaxaban&lt;/ulink&gt; to concentrate on the development of apixaban [&lt;ulink linkType="Reference" linkID="591298"&gt;591298&lt;/ulink&gt;] and, in 2007, the company filed patent applications for an aqueous injectable form of apixaban, comprising a solubilizing agent such as a substituted-beta-cyclodextrin [&lt;ulink linkType="Patent" linkID="PA3468501"&gt;WO-2007022165&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The key step in the synthesis of apixaban is the [3+2]-cycloaddition of (Z)ethyl 2-chloro-2-(2-(4-methoxyphenyl)-hydrazono)acetate and 1-(4-iodo-phenyl)-3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one. The chloro-hydrazone was prepared by diazotization of 4-anisidine with subsequent Japp-Klingemann reaction with ethyl 2-chloroacetoacetate. The starting dihydropyridone was synthesized via N-acylation of 4-iodo- or 4-nitro-aniline with 5-bromovaleryl chloride, followed by cyclization, gem-dichlorination, dehydrohalogenation and C3-amination of the dihydropyridone ring with morpholine. A mixture of starting chlorohydrazone, dihydropyridone and triethylamine in toluene was refluxed for 24 h to produce ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate (yield 71%). Beta-Valerolactam, potassium carbonate and DMSO were added to the tetrahydropyrazolopyridinone intermediate, and degassed with N2, which was followed by the addition of copper iodide and heated at 130degC for 24 h to produce 1-(4-methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,-7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester. The intermediate ester was treated with 5% NH3 in ethylene glycol and the mixture was heated to 120degC for 4 h in a sealed vessel, worked-up and chromatographed to produce apixaban (yield 76%) in 95% purity [&lt;ulink linkType="Reference" linkID="852586"&gt;852586&lt;/ulink&gt;]. Alternative syntheses of apixaban and the intermediate chlorohydrazone and dihydropyridone were described in &lt;ulink linkType="Patent" linkID="PA204222"&gt;WO-03026652&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3433539"&gt;WO-2007001385&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Introduction of either the phenyl piperidinone or the phenyl pyridinone P4 groups into the anthranilamide scaffold forms potent new Factor Xa inhibitors, one of which had efficacy comparable to apixaban in a rabbit arteriovenous (AV)-shunt model of thrombosis. However, this compound had a shorter half-life than apixaban and was unlikely to be developed further [&lt;ulink linkType="Reference" linkID="921959"&gt;921959&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;X-Ray crystallography has determined that the structure of apixaban bound to Factor Xa is a tight inhibitor-enzyme complex, a binding mode similar to &lt;ulink linkType="Drug" linkID="32750"&gt;razaxaban&lt;/ulink&gt;. The pendant P4 phenyllactam of apixaban is responsible for interaction with the active center of Factor Xa in a complementary manner [&lt;ulink linkType="Reference" linkID="852586"&gt;852586&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;&lt;subtitle&gt;In vitro&lt;/subtitle&gt;In vitro experiments using platelet-poor plasma from healthy volunteers demonstrated that apixaban is a potent and highly selective inhibitor of free Factor Xa (Ki = 0.08 nM) with minimal (Ki ~ 3 microM) affinity for thrombin, plasma kallikrein and chymotrypsin, and negligible affinity for trypsin and all other tested serine proteases (Ki &amp;gt; 15 microM). The inhibitory effects of apixaban on Factor Xa were reversible; the association rate was 2 x 10(7) M/s and dissociation half-life was 3.4 min [&lt;ulink linkType="Reference" linkID="884668"&gt;884668&lt;/ulink&gt;]. The pharmacodynamic effects of apixaban on in vitro thrombin generation were confirmed by detailed kinetic analysis of the binding of apixaban to Factor Xa using a thrombogram method and in silico thrombin generation models with platelet-poor human plasma. Apixaban rapidly reacted with Factor Xa (stopped-flow spectroscopic Kon = 2 x 10(7) M/s), bound with high affinity (Ki = 0.3 nM at 37degC), and noncompetitively inhibited prothrombin activation. Lag time and time-to-peak thrombin concentration increased by 2-fold at 200 and 300 nM apixaban, respectively. Apixaban reduced the maximum thrombin generation rate (IC50 = 35 nM) and peak thrombin concentration (IC50 = 70 nM) [&lt;ulink linkType="Reference" linkID="921994"&gt;921994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In platelet-poor human plasma, the human plasma concentration required to double the clotting time in coagulation activity tests of prothrombin time (PT) was 3.6 microM, in tests of APTT was 7.4 microM and in the HepTest assay (which quantitates heparin, LMWH and heparinoids) was 0.4 microM [&lt;ulink linkType="Reference" linkID="884668"&gt;884668&lt;/ulink&gt;]. The Factor Xa-inhibitory activity of apixaban was also observed in plasma from rabbits (Ki = 0.17 nM), dogs (Ki = 2.6 nM) and rats (Ki = 1.3 nM) [&lt;ulink linkType="Reference" linkID="884668"&gt;884668&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The incubation of apixaban with calcium chloride/phospholipid-induced clots, using Factor Va and prothrombin as stimulators, demonstrated that apixaban was more effective than heparin in vitro against human clot-bound Factor Xa (IC50 = 1.7 nM and 1.2 microg/ml, respectively), which was estimated by the release of prothrombin fragments 1 and 2 [&lt;ulink linkType="Reference" linkID="914226"&gt;914226&lt;/ulink&gt;]. Furthermore, apixaban indirectly inhibited tissue factor-induced aggregation of healthy human platelets with an IC50 value of 817 nM, although these effects were weaker compared with &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt; (IC50 = 35 nM) and &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; (IC50 = 312 nM). None of the three compounds affected platelet aggregation induced by ADP, collagen or thrombin receptor-activating peptide; in contrast to &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt;, neither apixaban nor &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; had an effect on ecarin-induced platelet aggregation [&lt;ulink linkType="Reference" linkID="859578"&gt;859578&lt;/ulink&gt;]. This effect on platelet function (ie, arterial thromboses) indicated the potential relevance of apixaban to the clinical setting.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vivo&lt;/subtitle&gt;The excellent in vitro anti-Factor Xa efficacy of apixaban was confirmed in studies using animal models. ED50 values for the inhibition of thrombosis (the dose that reduced thrombus weight or increased blood flow by 50% of the level in controls) were determined for apixaban (iv), &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; (iv) and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (po) in three rabbit models. In AV-shunt thrombosis, venous thrombosis and carotid arterial thrombosis models, ED50 values for apixaban were 0.27 +/- 0.03, 0.11 +/- 0.03 and 0.07 +/- 0.02 mg/kg/h, respectively; ED50 values for &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; were 0.05 +/- 0.01, 0.05 +/- 0.01 and 0.27 +/- 0.08 mg/kg/h, respectively; and ED50 values for &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; were 0.53 +/- 0.04, 0.27 +/- 0.01 and 0.08 +/- 0.01 mg/kg/day, respectively. In the AV-shunt thrombosis model, thrombus weight was reduced 98, 86 and 77% by apixaban (3 mg/kg/h), fondaparinux (1 mg/kg/h) and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (3 mg/kg/day), respectively; in the venous thrombosis model, thrombus formation was reduced 83, 74 and 84% by apixaban (1 mg/kg/h), &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; (0.3 mg/kg/h) and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (3 mg/kg/day), respectively. In the carotid arterial thrombosis model, integrated blood was improved by approximately 73, 86 and 78% by apixaban (3 mg/kg/h), &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; (1 mg/kg/h) and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (3 mg/kg/day), respectively [&lt;ulink linkType="Reference" linkID="901580"&gt;901580&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In anesthetized rats, experimental thrombosis was induced either by injection of FeCl2 into the vena cava and carotid artery or by infusion of tissue factor into the vena cava or an extracorporeal AV shunt. Apixaban was infused intravenously 60 min before the induction of thrombosis; doses of 0.1 to 3 mg/kg/h dose-dependently increased PT by 1.3- to 3.9-fold compared with untreated controls. Apixaban (3 mg/kg/h) significantly decreased thrombus weight by 62 +/- 4 to 90 +/- 2% in all models tested. Projected doses required for a 50% reduction in thrombus weight (expected to be sufficient to prevent vascular occlusion) ranged from 0.4 mg/kg/h in the FeCl2-induced vena cava thrombosis model to 1.9 mg/kg/h in the tissue factor-induced vena cava thrombosis model. The lowest apixaban dose able to preserve carotid blood flow at the pre-injury level was 0.3 mg/kg/h [&lt;ulink linkType="Reference" linkID="859902"&gt;859902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The rabbit models of AV-shunt thrombosis and venous thrombosis were used to compare antithrombotic effectiveness of apixaban with &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;. Apixaban (0.03 to 3 mg/kg/h), &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; (0.006 to 0.75 mg/kg/h) or &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; (0.01 to 1 mg/kg/h) were infused intravenously 30 to 60 min before the initiation of thrombosis, and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (0.1 to 3 mg/kg/day) was administered orally for 4 days before the experiments. A 50% reduction in thrombus weight in the AV-shunt thrombosis and venous thrombosis model was observed at 0.27 +/- 0.03 and 0.11 +/- 0.02 mg/kg/h, respectively, for apixaban; 0.04 +/- 0.01 and 0.05 +/- 0.01 mg/kg/h, respectively, for &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt;; 0.05 +/- 0.01 and 0.05 +/- 0.005 mg/kg/h, respectively, for &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt;; and 0.53 +/- 0.04 and 0.27 +/- 0.02 mg/kg, respectively, for &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;. Although intravenous administration of apixaban, &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; as a bolus followed by continuous infusion after thrombus formation in the venous thrombosis model resulted in the arrest of thrombus growth, only apixaban (0.6 mg/kg plus 0.87 mg/kg/h) was able to reduce thrombus weight (from 38 +/- 2 to 26 +/- 4 mg, p &amp;lt; 0.05) [&lt;ulink linkType="Reference" linkID="857919"&gt;857919&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a further study in a venous thrombosis rabbit model, apixaban (iv) was compared with &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (po). Both drugs dose-dependently inhibited thrombus formation, with apixaban demonstrating an IC50 value of 0.16 +/- 0.04 microM. At ID80 doses, apixaban increased ex vivo APTT by 1.4 +/- 0.1-fold over controls and PT by 1.7 +/- 0.1-fold over controls, while &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; increased PT by 4.5 +/- 0.1-fold over controls [&lt;ulink linkType="Reference" linkID="746824"&gt;746824&lt;/ulink&gt;]. Moreover, in a study in rats, dogs and chimpanzees administered apixaban (iv), the ex vivo apparent Ki values based on PT were approximately 1.8, 7.2 and 3.2 microM, respectively, and the apparent Ki value for the HepTest assay was approximately 1.0 microM in dogs [&lt;ulink linkType="Reference" linkID="914222"&gt;914222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;According to current clinical trends of the combined administration of different anticoagulant/antiplatelet drugs, the effectiveness of apixaban co-administered with aspirin, &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, heparin, &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; was tested before beginning clinical trials. Apixaban in combination with aspirin and/or &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; was studied in rabbit models of electrically induced carotid artery thrombosis and cuticle bleeding time (BT). Control thrombus weight was 8.6 +/- 0.9 mg and intravenous apixaban at 0.04 and 0.30 mg/kg/h reduced thrombus weight by 20 and 50%, respectively. Co-administration of aspirin (1 mg/kg/h) significantly enhanced the anti-thrombotic properties of apixaban at ED20 and ED50 doses (7.34 +/- 0.5 mg versus 5.3 +/- 0.3 and 3.6 +/- 0.3, respectively). Co-administration of apixaban at the ED20 dose with aspirin (1 mg/kg/h) and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; (1 and 3 mg/kg/day) had significantly more potent antithrombotic effects than aspirin or &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; as single agents (5.3 +/- 0.3 versus 2.9 +/- 0.3 and 0.7 +/- 0.1 mg, respectively) [&lt;ulink linkType="Reference" linkID="914203"&gt;914203&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The antithrombotic effects of the combination of apixaban with either heparin or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (all iv) were determined by analysis of thrombus reduction in AV-shunt thrombosis and cuticle BT models in rabbits. Thrombus formation was reduced dose-dependently by the drugs as single agents; ID50 values were 0.27 mg/kg/h for apixaban, 20 U/kg/h for heparin and 0.28 mg/kg/h for &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt;. When co-administered at their ID50 doses, apixaban significantly enhanced the antithrombotic effects of heparin and with &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt;; thrombus reductions were 46 +/- 3% for apixaban alone, 41 +/- 4% for heparin alone, 43 +/- 1% for &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; alone, and 90 +/- 1 and 81 +/- 2% for the combination of apixaban with heparin and &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt;, respectively [&lt;ulink linkType="Reference" linkID="914074"&gt;914074&lt;/ulink&gt;]. In a similar rabbit model, apixaban was at least as effective as the direct thrombin inhibitor &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; and more effective than aspirin in the prevention of arterial thrombosis. The antithrombotic ID50 value (mg/kg + mg/kg/h) was 0.11 +/- 0.17 for apixaban and 0.06 +/- 0.023 for &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt;. At ID80 doses, apixaban moderately increased the ex vivo APTT to 1.6 +/- 0.1-fold over controls and PT to 1.5 +/- 0.04-fold over controls, and did not change the thrombin time [&lt;ulink linkType="Reference" linkID="811572"&gt;811572&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Bleeding is a common and potentially life-threatening complication of all anticoagulants, especially when higher doses are used. The potential risk of bleeding upon administration of apixaban (0.1, 0.3, 1 and 3 mg/kg/h iv) was tested in a rat thrombosis model. Apixaban significantly and dose-dependently prolonged cuticle BT by 1.34 +/- 0.12- and 2.13 +/- 0.17-fold over untreated controls at doses of 1 and 3 mg/kg/h, respectively; no effect was seen at 0.1 and 0.3 mg/kg/h. In comparison, aspirin (10 mg/kg) increased BT by 1.42 +/- 0.1-fold over the control [&lt;ulink linkType="Reference" linkID="859902"&gt;859902&lt;/ulink&gt;]. In rabbit models of thrombosis and hemostasis, the doses of apixaban required to increase BT by 3-fold were &amp;gt; 3 mg/kg/h, which far exceeds therapeutic doses. For &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;, the respective doses were &amp;gt; 3 mg/kg/h and 0.7 mg/kg/day, respectively [&lt;ulink linkType="Reference" linkID="901580"&gt;901580&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;When used at doses sufficient to prevent 80 to 90% of thrombus formation in rabbit models of AV-shunt thrombosis and venous thrombosis, apixaban caused less of an increase in cuticle BT (20 +/- 2%) than &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; (30 +/- 5%), &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; (500 +/- 10%) or &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (502 +/- 20%). Increases in BT of 3-fold were observed at doses of &amp;gt; 3 mg/kg/h for apixaban and &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt;, at 0.24 mg/kg/h for &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; and at 0.70 mg/kg/h for &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="857919"&gt;857919&lt;/ulink&gt;]. In a venous thrombosis rabbit model, apixaban at the antithrombotic ID80 dose caused a significantly lower increase in BT (by 9 +/- 4%) than &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (516 +/- 24%) [&lt;ulink linkType="Reference" linkID="746824"&gt;746824&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The addition of aspirin (1 mg/kg/h) to ED20 and ED50 doses of apixaban enhanced antithrombotic efficacy in rabbit models of electrically induced carotid artery thrombosis and cuticle BT, without significantly altering BT (190 +/- 7 versus 181 +/- 9 and 225 +/- 11 s, respectively; control BT was 181 s). The addition of &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; (1 and 3 mg/kg/day) to the combination of the ED20 doses of apixaban and aspirin led to moderate increases in BT of 1.45- and 2.1-fold for 1 and 3 mg/kg/day of &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, respectively (p &amp;lt; 0.05) [&lt;ulink linkType="Reference" linkID="914203"&gt;914203&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the rabbit AV-shunt thrombosis and cuticle BT models, apixaban, heparin and enoxaparin at their ID50 doses increased BT by 12, 24 and 5%, respectively. The co-administration of apixaban with heparin or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; resulted in increases in BT of 27 +/- 5 and 21 +/- 3%, respectively [&lt;ulink linkType="Reference" linkID="914074"&gt;914074&lt;/ulink&gt;]. In a similar rabbit model, apixaban was as effective as &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; and more effective than aspirin, and had a wider therapeutic index. At ID80 doses, apixaban and &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; increased BT by 132 and 18,520%, respectively, and aspirin (3 mg/kg/h) increased BT by 673% [&lt;ulink linkType="Reference" linkID="811572"&gt;811572&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;These studies predict a wide therapeutic index for apixaban based on the prevention of occlusive thrombosis in a variety of experimental models without excessive BT prolongation. At the antithrombotic doses studied, apixaban did not alter blood pressure and heart rate [&lt;ulink linkType="Reference" linkID="746824"&gt;746824&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="811572"&gt;811572&lt;/ulink&gt;], suggesting its potential safety in patients with cardiovascular disorders.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;&lt;subtitle&gt;Preclinical studies&lt;/subtitle&gt;In a rat thrombosis model, the administration of apixaban (0.1, 0.3, 1 and 3 mg/kg/h iv) resulted in plasma concentrations of 0.3, 1.4, 5.0 and 12.2 microM, respectively [&lt;ulink linkType="Reference" linkID="859902"&gt;859902&lt;/ulink&gt;]. The solubility of apixaban was approximately 50 microg/ml. In a human liver microsome assay, apixaban was stable, had a half-life &amp;gt; 100 min and demonstrated a moderate to high membrane permeability value in Caco2 cells (apparent permeability [Papp] = 0.9 x 10(-6) cm/s) [&lt;ulink linkType="Reference" linkID="852586"&gt;852586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Apixaban was well absorbed in chimpanzees, dogs and rats; mean oral bioavailability was 51, 88 and 34%, respectively. The mean volume of distribution of apixaban was 0.17 l/kg in chimpanzees, 0.20 to 0.29 l/kg in dogs and 0.31 l/kg in rats, suggesting apixaban was mainly distributed (30 to 50%) to the blood, the target organ of therapeutic action. Given that the unbound serum fraction of apixaban constitutes approximately 13% in humans, 5% in chimpanzees, 8% in dogs and 4% in rats, the small volume of distribution may be attributable to limited extravascular tissue distribution rather than to extensive plasma protein binding. The systemic clearance of apixaban was &amp;lt; 3% of hepatic blood flow in chimpanzees (0.018 l/h/kg) and dogs (0.052 l/h/kg), and &amp;lt; 10% in rats (0.26 l/h/kg) [&lt;ulink linkType="Reference" linkID="746803"&gt;746803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A low rate of in vitro metabolic clearance of apixaban occurred in human, chimpanzee and dog liver microsome and human hepatocyte assays. The main metabolite identified in vitro was the O-demethylated product, formed mainly by cytochrome P (CYP)3A4 in human liver microsomes. Multiple pathways were involved in the elimination of apixaban, including renal and intestinal excretion. Biliary clearance was low in dogs (~ 2% of the systemic learance) [&lt;ulink linkType="Reference" linkID="746803"&gt;746803&lt;/ulink&gt;]. In cDNA-expressed enzyme systems and human liver microsomes, apixaban did not inhibit the activity of CYP isoforms 1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, and did not induce CYPs 1A2, 2B6 or 3A4 in human hepatocytes. The absence of glutathione adducts in dog, rat and human hepatocyte and liver microsome incubations of apixaban in the presence of glutathione [&lt;ulink linkType="Reference" linkID="746803"&gt;746803&lt;/ulink&gt;] indicated that reactive metabolites of apixaban were unlikely to be produced.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical trials&lt;/subtitle&gt;Following the administration of a single dose of apixaban (0.5 to 2.5 mg as solution or 5.0 to 50.0 mg in tablet po) or placebo to healthy male volunteers (n = 8), the plasma concentration of apixaban reached maximum levels at 1.5 to 3.5 h; exposure increased dose-proportionally. The terminal half-life of apixaban ranged from 3.6 to 27.0 h, with a multiphasic decline in plasma concentration [&lt;ulink linkType="Reference" linkID="811343"&gt;811343&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a 7-day pharmacokinetic study, oral apixaban (2.5, 5.0, 10.0 and 25.0 mg bid, 10.0 and 25.0 mg/day) or placebo was administered to healthy volunteers (n = 8). Maximum plasma concentration was reached approximately 3 h after administration, and exposure increased in a dose-related manner on days 1 and 7. By day 3, apixaban concentration reached steady state (accumulation index 1.3 to 1.9). The terminal half-life of apixaban, determined after the last dose, ranged from 8 to 15 h; fluctuations of plasma concentration were lower for the twice-daily regime [&lt;ulink linkType="Reference" linkID="811344"&gt;811344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In an open-label study, healthy volunteers received digoxin (0.25 mg) every 6 h on day 1 then once daily. On days 11 to 20, apixaban (20 mg) was co-administered once daily. The point estimates for the ratios of geometric means of digoxin Cmax and AUCTAU (the area under the plasma concentration-time curve for a dosing interval) alone (0.9) or in combination with apixaban (0.92) were similar, indicating a lack of interaction betweenthese drugs [&lt;ulink linkType="Reference" linkID="884666"&gt;884666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In a randomized, double-blind, placebo-controlled clinical trial, healthy male volunteers (n = 6) received a single dose of apixaban (0.5 to 2.5 mg as solution or 5.0 to 50.0 mg in tablet po) and two volunteers received placebo. Clotting times increased in a dose-related manner; the highest dose of apixaban (50 mg) increased APTT by 1.2-fold, international normalized ratio (INR) by 1.5-fold and modified PT by 2.6-fold [&lt;ulink linkType="Reference" linkID="811343"&gt;811343&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A randomized, double-blind, placebo-controlled clinical trial assessed treatment for 7 days with apixaban (2.5, 5.0, 10.0 and 25.0 mg bid, 10.0 and 25.0 mg/day po) in healthy volunteers (n = 6) and placebo in two volunteers. Clotting times closely corresponded to plasma concentrations and increased in a dose-related manner. Following 7 days of administration, the highest apixaban dose tested (25 mg bid) increased APTT by 1.2-fold, INR by 1.5-fold and modified PT by 3.2-fold [&lt;ulink linkType="Reference" linkID="811344"&gt;811344&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In the Botticelli DVT (named after the investigators), double-blind, open-label, dose-ranging clinical trial, patients (n = 520) with symptomatic DVT were randomized to receive apixaban (5 or 10 mg bid or 20 mg/day po) or conventional treatment with LMWH or fondaparinux, followed by open-label treatment with a VKA (dose adjusted to an INR of 2 to 3). A bilateral venous compression ultrasound of the legs and a perfusion lung scan were performed within 36 h of randomization and at 84 days. After treatment for 84 to 91 days, no significant difference was reported between apixaban and the control group. The primary outcome (a composite of symptomatic recurrent VTE and asymptomatic deterioration of bilateral compression ultrasound or perfusion lung scan) was met in 4.7% of patients treated with apixaban (95% confidence interval [CI]: 2.8 to 7.5%) and in 4.2% of control patients (95% CI: 1.4 to 9.6%). The primary efficacy outcome rates for apixaban were 6.0% for 5.0 mg twice daily, 5.6% for 10.0 mg twice daily and 2.6% for 20.0 mg once daily. The rates of symptomatic VTE were 2.6, 3.2 and 1.7% for the respective apixaban doses and 2.5% for conventional treatment [&lt;ulink linkType="Reference" linkID="922015"&gt;922015&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="922017"&gt;922017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a randomized, double-blind, parallel-group, dose-response clinical trial, patients (n = 1238) undergoing total knee replacement were blindly randomized to receive apixaban (5, 10 or 20 mg/day po, administered as either qd or bid doses) or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (30 mg sc bid), or received oral &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (target INR 1.8 to 3.0) on an open-label basis. Treatment with apixaban or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; began at 12 to 24 h after surgery; the &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; dose was titrated from the evening of the day of surgery. After 10 to 14 days of the treatment, bilateral venography was performed and patients were further treated according to the discretion of the attending physician. After 42 days of follow up, the primary endpoint (composite of all VTE events plus all-cause death rate) was significantly lower in the apixaban group (8.6%) than in the &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (15.6%, p &amp;lt; 0.02) or &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (26.6%, p &amp;lt; 0.001) groups. A trend toward a dose-related decrease in VTE events plus all-cause death rate was reported when once- and twice-daily apixaban doses were combined as a total daily dose (10.6% for 5 mg, 8.6% for 10 mg and 6.8% for 20 mg, p = 0.09). The composite VTE plus all-cause death rates for 2.5 mg apixaban twice daily (9.9%; 95%CI of 5.1 to 17.0) or 5.0 mg once daily (11.3%; 95% CI of 5.8 to 19.4) were lower than in the &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (15.6%; 95% CI of 9.4 to 23.8) and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (26.6%; 95% CI of 18.6 to 35.9) groups. For the composite outcome of proximal DVT plus PE plus all-cause death, each apixaban group had a lower event rate (0 to 2.7%) than the &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; group (4.6%); the rate was 1.8% for &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="750221"&gt;750221&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="864753"&gt;864753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A subsequent model-based analysis of the results of this total knee replacement surgery clinical trial used 4694 drug concentration data points from patients (n = 855) who received one of six doses of apixaban. A clinical utility function was constructed to quantify the risk-benefit of all dose arms, and exposure-clinical outcome analysis indicated that a dose regimen of 2.5 mg twice daily had superior clinical utility to other dosing regimens in terms of clinical efficacy (all-cause death plus VTE) and safety (total bleeding) [&lt;ulink linkType="Reference" linkID="922020"&gt;922020&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="5873"&gt;APPRAISE-1&lt;/ulink&gt;) to assess the safety of apixaban in patients (n = 1771) with recent ACS is ongoing. Patients were to receive apixaban (2.5 mg bid or 10.0 mg/day po) or placebo for 26 weeks. The primary outcome measure was the reduction in the incidence of major and clinically relevant non-major bleeding; the secondary outcome measure was the composite of death, non-fatal myocardial infarction, severe recurrent ischemia and non-hemorrhagic stroke, as well as all bleeding events [&lt;ulink linkType="Reference" linkID="855304"&gt;855304&lt;/ulink&gt;]. A non-significant relative risk reduction in cardiovascular death, non-fatal heart attack, severe recurrent ischemia and non-hemorrhagic stroke was observed in 27 and 39% of patients receiving 2.5 and 10 mg, respectively, compared with placebo [&lt;ulink linkType="Reference" linkID="939750"&gt;939750&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A second ongoing phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="7886"&gt;ADVOCATE&lt;/ulink&gt;) was designed to assess the safety, tolerability and effectiveness of oral apixaban in preventing thrombotic events in patients with advanced or metastatic cancer administered chemotherapy for &amp;gt; 90 days. The administration of apixaban (5 mg/day) or placebo for 12 weeks was to be initiated within 6 weeks of starting chemotherapy; expected enrollment was 160 patients [&lt;ulink linkType="Reference" linkID="924955"&gt;924955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In two randomized, double-blind, active-controlled, multicenter clinical trials – &lt;ulink linkType="Protocol" linkID="5701"&gt;ADVANCE-1&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="7852"&gt;ADVANCE-2&lt;/ulink&gt; – the safety and efficacy of apixaban (po) versus &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (sc) in preventing DVT and PE after knee replacement surgery were to be evaluated. Patients (n = 3670 in each trial) were to receive apixaban (2.5 mg bid) plus placebo or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (30 mg bid in ADVANCE-1 and 40 mg/day in ADVANCE-2) plus placebo for 12 days. Primary outcome measures were a combination of measures of asymptomatic and symptomatic DVT, non-fatal PE and all-cause death, and non-inferiority compared with &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="915530"&gt;915530&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="926784"&gt;926784&lt;/ulink&gt;]. In ADVANCE-1, secondary outcome measures included the following combined endpoints: proximal DVT, non-fatal PE and all-cause death; symptomatic DVT, non-fatal and fatal PE; major and non-major bleeding events; and myocardial infarction and stroke [&lt;ulink linkType="Reference" linkID="926784"&gt;926784&lt;/ulink&gt;]. At the time of publication, preliminary results indicated that the rate of achieving the primary endpoint was similar between apixaban (9%) and &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (8.9%) and that the primary endpoint was not met [&lt;ulink linkType="Reference" linkID="938327"&gt;938327&lt;/ulink&gt;]. In ADVANCE-2, secondary outcome measures included a combination of adjudicated asymptomatic and symptomatic proximal DVT, non-fatal PE and VTE-related death. The ADVANCE-2 study was recruiting patients at the time of publication and the estimated completion date was January 2009 [&lt;ulink linkType="Reference" linkID="915530"&gt;915530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A similar randomized, double-blind, active-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="7849"&gt;ADVANCE-3&lt;/ulink&gt;) was designed to evaluate the safety and efficacy of apixaban (po) versus &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (sc) in preventing DVT and PE in patients (n = 4424) after hip replacement surgery. Patients were to receive apixaban (2.5 mg bid) plus placebo or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (40 mg/day) plus placebo for 5 weeks. Primary outcome measures were a combination of asymptomatic and symptomatic DVT, non-fatal PE and all-cause death; secondary outcome measures included combined endpoints: proximal DVT, non-fatal PE and VTE-related death, and major and non-major bleeding events. Recruitment was underway at the time of publication and the estimated study completion date was February 2009 [&lt;ulink linkType="Reference" linkID="915533"&gt;915533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A further randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="4889"&gt;ADOPT&lt;/ulink&gt;) to determine the safety and efficacy of apixaban (po) in comparison with &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (sc) in preventing DVT and PE in patients (n = 7502) hospitalized with congestive heart failure, acute respiratory failure, infection (without septic shock), acute rheumatic disorder or inflammatory bowel disease was underway. Patients were to receive apixaban (2.5 mg bid) for 30 days plus placebo for 6 to 14 days or &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (40 mg/day) for 6 to 14 days plus placebo for 30 days. Primary outcome measures were the composite of VTE and VTE-related death; secondary outcome measures included all-cause death, major bleeding and clinically relevant non-major bleeding. Recruitment had commenced at the time of publication and the estimated study completion date was March 2009 [&lt;ulink linkType="Reference" linkID="924956"&gt;924956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="9082"&gt;AMPLIFY&lt;/ulink&gt;) to assess the effects of apixaban (po) in preventing VTE recurrence or death in patients (n = 3625) with DVT, patients were to receive either &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; (1 mg/kg sc bid until INR &gt;/= 2) with oral &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (INR 2 to 3) for 6 months or apixaban (10 mg bid) for 7 days, followed by apixaban (5 mg bid) for 6 months. Primary outcome measures were the recurrence of VTE events or death; secondary outcome measures included the incidence of bleeding. The study was not yet recruiting at the time of publication and the estimated completion date was July 2011 [&lt;ulink linkType="Reference" linkID="924958"&gt;924958&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A randomized, double-blind, multicenter, clinical trial (&lt;ulink linkType="Protocol" linkID="8495"&gt;AMPLIFY-EXT&lt;/ulink&gt;) was designed to assess the efficacy and safety of apixaban (po) in preventing VTE recurrence or death in patients (n = 2438) with a clinical diagnosis of DVT or PE who have already completed their standard treatment for DVT or PE. Patients were to receive apixaban (2.5 or 5.0 mg bid) or placebo for 12 months. Primary outcome measures were VTE recurrence or death; secondary outcome measures included the incidence of bleeding. Recruitment had commenced at the time of publication and the estimated study completion date was January 2011 [&lt;ulink linkType="Reference" linkID="924959"&gt;924959&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In addition, two phase III clinical trials to assess the effectiveness of apixaban in preventing stroke in patients with AF were ongoing. In the first, a randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="4979"&gt;AVERROES&lt;/ulink&gt;), the effectiveness of apixaban (po) was to be compared with aspirin (po) in preventing stroke or systemic embolism in patients (n = 6160) with permanent or persistent AF who have at least one additional risk factor for stroke, but who cannot be treated with vitamin K inhibitors. Patients were to receive apixaban (5.0 mg bid or 2.5 mg in selected patients) or aspirin (81 to 324 mg/day) for 36 months. Primary outcome measures were the composite of reductions in the occurrence of stroke or systemic embolism in treated patients. Secondary outcome measures were the composite outcome of the incidence of stroke, systemic embolism, myocardial infarction or vascular death (major vascular events). Recruitment was underway at the time of publication and the estimated study completion date was April 2010 [&lt;ulink linkType="Reference" linkID="924960"&gt;924960&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The second trial, a randomized, double-blind, multicenter trial (&lt;ulink linkType="Protocol" linkID="4965"&gt;ARISTOTLE&lt;/ulink&gt;), was designed to determine whether apixaban (po) was as effective as standard therapy (oral &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;) in preventing stroke and systemic embolism in patients (n = 16,455) with AF who have at least one additional risk factor for stroke. Patients were to receive apixaban (5 mg bid) or &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; (2 mg, adjusted to an INR 2 to 3). Primary outcome measures included the incidence of confirmed stroke or systemic embolism, and secondary outcome measures included confirmed ischemic stroke, hemorrhagic stroke, systemic embolism and all-cause death. Recruitment had been completed at the time of publication and the estimated study completion date was May 2010 [&lt;ulink linkType="Reference" linkID="868428"&gt;868428&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;Apixaban was safe and well tolerated at all doses tested in volunteers receiving 0.5 to 2.5 mg as solution or 5.0 to 50.0 mg in tablet form. No changes in BT were observed and three mild bleeding events resolved without treatment [&lt;ulink linkType="Reference" linkID="811343"&gt;811343&lt;/ulink&gt;]. Similarly, there were no withdrawals from the study as a result of adverse events in the phase I clinical trial with apixaban (0.5 to 50.0 mg/day) and, during 7 days of administration, the drug was well tolerated at all doses. No changes in BT were observed and three mild bleeding events resolved without treatment [&lt;ulink linkType="Reference" linkID="811344"&gt;811344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a randomized, double-blind, crossover clinical trial (&gt;/= 7 day washout), the effect of treatment for 3 days with apixaban (10 or 50 mg/day po) or placebo on the QTc interval (measure of cardiac rhythm) was assessed in healthy volunteers (n = 40). Alternatively, a single dose of open-label &lt;ulink linkType="Drug" linkID="12978"&gt;moxifloxacin&lt;/ulink&gt; (400 mg) was administered on day 3. ECGs were obtained and independently analyzed on days 1 and 3 and the time-matched difference between the mean deltaQTc of apixaban or &lt;ulink linkType="Drug" linkID="12978"&gt;moxifloxacin&lt;/ulink&gt; compared with placebo was estimated at each time point. The upper 95% CI for the maximum difference between apixaban and placebo was &amp;lt; 10 ms, suggesting that apixaban had no clinically significant effect on QTc interval. The maximum placebo-adjusted DQTcf (QT corrected using Fridericia's formula) was 1.51 ms (upper 95% CI: 3.71 ms) at 50 mg and 1.36 ms (upper 95% CI: 3.54 ms) at 10 mg apixaban, indicating the safety of apixaban in terms of proarrhythmic risk. Assay sensitivity was confirmed by demonstration that the lower 95% CI was 8.07 ms for &lt;ulink linkType="Drug" linkID="12978"&gt;moxifloxacin&lt;/ulink&gt; compared with placebo [&lt;ulink linkType="Reference" linkID="887408"&gt;887408&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Individuals treated with apixaban and digoxin in a phase I clinical trial tolerated the combination well and no serious adverse events or major bleeding-related events were reported. All non-serious adverse events were resolved without treatment [&lt;ulink linkType="Reference" linkID="884666"&gt;884666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II clinical trial in patients undergoing knee surgery, the incidence of major bleeding in apixaban-treated patients ranged from 0 (2.5 mg bid) to 3.3% (20 mg/day), with comparable results for once- and twice-daily administration. Notably, with the exception of one gastrointestinal bleeding event (gastric ulcer) and one case of hematouria, all major bleeding events were associated with knee surgery (hematoma and ecchymoses). No major bleeding was observed in the &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; groups. The rates of minor bleeding ranged from 0.7 to 7.2% for apixaban and were 4.0% for &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; and 5.3% for &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;. Only one potentially significant non-overt bleeding event was reported for apixaban (0.6%) and two events (1.3%) occurred with &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="864753"&gt;864753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Furthermore, in the same trial, one case of liver transaminase elevation by &amp;gt; 3-fold the upper limit of normal and one case of bilirubin increase by &amp;gt; 2-fold were recorded, both after 10-mg twice-daily doses of apixaban. However, these abnormal values were obtained on the first day after knee surgery and had returned to threshold levels by the next measurement. One patient developed a neurological syndrome classified as amyotrophic lateral sclerosis, but a retrospective analysis determined that the first signs of the disorder had presented before initiation of apixaban treatment. Guillain-Barre Syndrome (progressive polyneuropathy) was observed during the follow-up period and could be related to apixaban therapy [&lt;ulink linkType="Reference" linkID="864753"&gt;864753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the Botticelli DVT dose-ranging clinical trial, the rate of major bleeding events was 0.8% for 5.0 mg twice- daily apixaban, 0.0% for 10.0 mg twice daily and 0.8% for 20.0 mg once daily; no major bleeding events were observed in the conventional treatment group. The principal safety outcome (composite of major and clinically relevant, non-major bleeding) was met in 7.3% of the apixaban-treated patients compared with 7.9% of patients with referent treatment. The principal safety outcome rates for apixaban were 8.6% for 5.0 mg twice daily, 4.5% for 10.0 mg twice daily and 7.3% for 20 mg once daily [&lt;ulink linkType="Reference" linkID="922015"&gt;922015&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="922017"&gt;922017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Major bleeding plus clinically relevant non-major bleeding in the APPRAISE-1 was 5.7, 7.9 and 3% in patients receiving 2.5 and 10 mg apixaban and placebo, respectively. The incidences of major bleeding as assessed using the International Society of Thrombosis and Haemostasis (ISTH) standard scale were 1.6, 1.9 and 0.8%, respectively, and the discontinuation rates for bleeding were 1.9, 2.9 and 1.2%, respectively [&lt;ulink linkType="Reference" linkID="939750"&gt;939750&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;A generic structure of apixaban is claimed in the &lt;ulink linkType="Patent" linkID="IN2746060"&gt;WO-0039131&lt;/ulink&gt; patent family, with patents granted in Australia, China, Taiwan, Norway and Europe (&lt;ulink linkType="Patent" linkID="PA3424543"&gt;EP-01140941&lt;/ulink&gt;), as well as three issued US divisional patents (&lt;ulink linkType="Patent" linkID="PA3163827"&gt;US-06413980&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3016036"&gt;US-06673810&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA2949257"&gt;US-06858616&lt;/ulink&gt;). All patents expire or are presumed to expire in December 2019, except for &lt;ulink linkType="Patent" linkID="PA2949257"&gt;US-06858616&lt;/ulink&gt;, which expires in April 2020 because of a 125-day patent-term adjustment. The specific structure of apixaban is claimed in the &lt;ulink linkType="Patent" linkID="PA204222"&gt;WO-03026652&lt;/ulink&gt; family, including the issued US divisional patents &lt;ulink linkType="Patent" linkID="PA3062604"&gt;US-06967208&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3007381"&gt;US-06995172&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3511172"&gt;US-07371761&lt;/ulink&gt;, the first of which has the latest expiry (February 2023) due to a 139-day patent term adjustment. To date, no other patent offices have granted other applications from the &lt;ulink linkType="Patent" linkID="PA204222"&gt;WO-03026652&lt;/ulink&gt; family.&lt;/para&gt;&lt;para&gt;Further patenting activity has followed the standard pattern, with &lt;ulink linkType="Patent" linkID="PA3433539"&gt;WO-2007001385&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA2862219"&gt;WO-03049681&lt;/ulink&gt; claiming processes to produce apixaban, and &lt;ulink linkType="Patent" linkID="PA3217114"&gt;WO-2006078331&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3468501"&gt;WO-2007022165&lt;/ulink&gt; claiming its N-1 nonsolvate form and an injectable formulation, respectively. &lt;ulink linkType="Patent" linkID="PA3567070"&gt;US-20070259913&lt;/ulink&gt; specifically claims the use of apixaban for the treatment of thromboembolic events in patients with cancer.&lt;/para&gt;&lt;para&gt;In &lt;ulink linkType="Patent" linkID="PA3194200"&gt;WO-2006045756&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="22546"&gt;Boehringer Ingelheim&lt;/ulink&gt; claims the use of &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt; in combination with over 200 other antithrombotic agents, including apixaban. &lt;ulink linkType="Company" linkID="18201"&gt;EPIX Pharmaceuticals Inc&lt;/ulink&gt; has filed &lt;ulink linkType="Patent" linkID="PA3491316"&gt;WO-2007047608&lt;/ulink&gt;, claiming fibrin-targeting peptides conjugated to a variety of bioactive agents, including apixaban. Lastly, in &lt;ulink linkType="Patent" linkID="PA3239719"&gt;WO-2006106695&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="17665"&gt;Kissei Pharmaceutical Co&lt;/ulink&gt; claims the development of an assay for Factor Xa inhibitors, including apixaban. To date, no filings by &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; or &lt;ulink linkType="Company" linkID="18767"&gt;Pfizer&lt;/ulink&gt; have been published that claim combinations of apixaban with other drugs.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;Anticoagulant therapy has proven to be extremely efficient and is currently unavoidable as thromboprophylaxis for the management of patients with DVT, PE and a large proportion of patients with AF. However, pharmacokinetic limitations with VKAs highlight the need for a predictable, dose-dependent and safe alternative to traditional methods of anticoagulation. An oral formulation is crucial for conditions where prolonged and especially life-long treatment is required.&lt;/para&gt;&lt;para&gt;The two main classes of new oral anticoagulant drugs are the direct thrombin inhibitors and Factor Xa inhibitors. The effectiveness of oral direct thrombin inhibitors was first demonstrated in large-scale clinical trials with &lt;ulink linkType="Drug" linkID="17059"&gt;ximelagatran&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca plc&lt;/ulink&gt;), but &lt;ulink linkType="Drug" linkID="17059"&gt;ximelagatran&lt;/ulink&gt; was not approved for clinical practice because of hepatotoxic side effects [&lt;ulink linkType="Reference" linkID="563498"&gt;563498&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="759384"&gt;759384&lt;/ulink&gt;]. Another oral direct thrombin inhibitor, &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt;, appears to be both effective and safe in preventing thromboembolism after orthopedic surgery [&lt;ulink linkType="Reference" linkID="750136"&gt;750136&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="750233"&gt;750233&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="812366"&gt;812366&lt;/ulink&gt;], and has recently been launched [&lt;ulink linkType="Reference" linkID="926782"&gt;926782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The oral Factor Xa inhibitors are another promising alternative to current traditional anticoagulants. The first member of this class, &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt;, was effective and safe in patients with ACS and VTE [&lt;ulink linkType="Reference" linkID="431592"&gt;431592&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="681044"&gt;681044&lt;/ulink&gt;]. However, because it is an indirect inhibitor of Factor Xa, the effectiveness of &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; depends on levels of antithrombin III; additionally, it cannot be administered orally. Preclinical in vitro studies demonstrated that apixaban is a highly selective, reversible and potent inhibitor of both free and clot-bound Factor Xa, with additional antiprothrombinase activity. Moreover, apixaban inhibited tissue factor-induced platelet aggregation, indicating a potential applicability to the treatment of arterial thrombosis. This was confirmed in animal models, and apixaban was more effective than aspirin in the prevention of arterial thrombosis in rabbits. Results of the phase II clinical trial in patients with ACS should soon be available. Apixaban has also been successfully co-administered with aspirin, &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, heparin and &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt;, indicating its potential utility for the clinical setting of arterial thrombosis, providing that these findings are confirmed by the ongoing phase III clinical trials. Additionally, in preclinical studies, apixaban demonstrated similar efficacy to &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; in preventing thrombosis, with a better safety profile. Comparative clinical data on apixaban versus &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt; will be of specific importance because in large-scale clinical trials, fondaparinux was approximately 50% more effective than &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; in preventing VTE events after major orthopedic surgery, and had a significantly lower risk of bleeding complications [&lt;ulink linkType="Reference" linkID="470643"&gt;470643&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="681041"&gt;681041&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="854034"&gt;854034&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="925917"&gt;925917&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Bleeding is a common and potentially life-threatening complication attributable to all anticoagulants, especially when higher doses are used. The available preclinical studies predict a wide therapeutic window for apixaban, on the basis of the successful prevention of occlusive thrombosis in a variety of experimental models, without excessive BT prolongation. Apixaban demonstrated a good safety profile compared with &lt;ulink linkType="Drug" linkID="4476"&gt;fondaparinux&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="3284"&gt;lepirudin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;. Apixaban also demonstrated excellent pharmacokinetic and metabolic properties in preclinical studies, including a small volume of distribution, low systemic clearance, good oral bioavailability and multiple routes of elimination, which made it a promising candidate for further clinical development.&lt;/para&gt;&lt;para&gt;In healthy volunteers, apixaban dose-dependently inhibited Factor Xa activity. Single doses of apixaban were safe and well tolerated over a 100-fold dose range. Although apixaban is being administered on a twice-daily basis in the ongoing clinical trials, its pharmacokinetic characteristics indicate that it has the potential to be used once daily.&lt;/para&gt;&lt;para&gt;In a phase II clinical trial to assess the prevention of thromboembolic events in patients undergoing total knee replacement, apixaban was superior to &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt; therapy followed by &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;, and resulted in a low rate of bleeding. Even low doses of apixaban (2.5 mg bid) were effective in this category of patients. Additionally, a phase II clinical trial of apixaban indicated a similar efficacy and safety profile to traditional treatment for DVT. Apixaban, therefore, appears to have good utility as an anticoagulant. Ongoing phase III clinical trials are designed to evaluate the effectiveness and safety of apixaban in patients with DVT, AF, undergoing knee or hip replacement surgery, and in patients hospitalized for acute medical illness. Preliminary results from the phase III ADVANCE-1 trial indicated that apixaban met the primary efficacy endpoint with a similar rate as &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin sodium&lt;/ulink&gt;. Further knee surgery trials were subsequently considered by the companies and the drug was not expected to be submitted for approval for VTE in the second half of 2009 as previously planned [&lt;ulink linkType="Reference" linkID="938327"&gt;938327&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The promising preclinical and initial clinical results make apixaban a serious competitor to other new, oral anticoagulant drugs in late-stage clinical development, such as &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt;. Similar to apixaban, &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt; have a predictable dose-response relationship and do not require intensive monitoring [&lt;ulink linkType="Reference" linkID="769605"&gt;769605&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="831687"&gt;831687&lt;/ulink&gt;]. The advantage of apixaban is the wide therapeutic index observed in preclinical studies and a lack of known inter-drug interactions. Although no direct clinical comparisons of effectiveness and safety of apixaban with other novel oral anticoagulants are currently available, no cases of treatment-related headache were reported for apixaban, in contrast to &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="694476"&gt;694476&lt;/ulink&gt;]. Unlike Factor Xa inhibitors, direct thrombin inhibitors inactivate both plasma and fibrin-bound thrombin [&lt;ulink linkType="Reference" linkID="925948"&gt;925948&lt;/ulink&gt;]. This difference should theoretically make direct thrombin inhibitors more potent anticoagulants, but may also result in higher bleeding rates. Ongoing trials should determine the place of these investigational anticoagulants in the market, and help clinicians and patients to improve their management of thrombotic disorders.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1212066" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-30T00:00:00.000Z</StatusDate><Source id="1412952" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1408858" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="2073455" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-10T00:00:00.000Z</StatusDate><Source id="2073486" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-26T00:00:00.000Z</StatusDate><Source id="1449274" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-26T00:00:00.000Z</StatusDate><Source id="1449274" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-26T00:00:00.000Z</StatusDate><Source id="1386238" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073520" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073459" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-09-01T00:00:00.000Z</StatusDate><Source id="1353636" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-09-01T00:00:00.000Z</StatusDate><Source id="1353636" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1212066" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="1523066" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-29T00:00:00.000Z</StatusDate><Source id="1494583" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-29T00:00:00.000Z</StatusDate><Source id="2038395" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1338589" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-12T00:00:00.000Z</StatusDate><Source id="1404225" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073527" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073527" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="2038395" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073459" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073526" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-31T00:00:00.000Z</StatusDate><Source id="1435535" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073526" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-10T00:00:00.000Z</StatusDate><Source id="2073486" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="2073455" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-29T00:00:00.000Z</StatusDate><Source id="1494583" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-31T00:00:00.000Z</StatusDate><Source id="1435535" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-26T00:00:00.000Z</StatusDate><Source id="1449274" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-30T00:00:00.000Z</StatusDate><Source id="1412952" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-01T00:00:00.000Z</StatusDate><Source id="1464175" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073529" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-10-01T00:00:00.000Z</StatusDate><Source id="1570879" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073529" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-05-31T00:00:00.000Z</StatusDate><Source id="2073515" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="2038395" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-29T00:00:00.000Z</StatusDate><Source id="2038395" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-01T00:00:00.000Z</StatusDate><Source id="1464175" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-07-06T00:00:00.000Z</StatusDate><Source id="1347648" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1338589" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-12T00:00:00.000Z</StatusDate><Source id="1404225" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-07-15T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073520" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-27T00:00:00.000Z</StatusDate><Source id="1444818" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-26T00:00:00.000Z</StatusDate><Source id="1449274" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-26T00:00:00.000Z</StatusDate><Source id="1386238" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-07-15T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-07-06T00:00:00.000Z</StatusDate><Source id="1347648" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-05-31T00:00:00.000Z</StatusDate><Source id="2073515" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-27T00:00:00.000Z</StatusDate><Source id="1444818" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-11T00:00:00.000Z</StatusDate><Source id="1451337" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-25T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-25T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-28T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-11T00:00:00.000Z</StatusDate><Source id="1451337" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-11T00:00:00.000Z</StatusDate><Source id="1451337" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-11T00:00:00.000Z</StatusDate><Source id="1451337" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-28T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1149245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1149245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1149245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1149245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1149245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1149245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-21T00:00:00.000Z</StatusDate><Source id="1253896" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-26T00:00:00.000Z</StatusDate><Source id="1146782" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-26T00:00:00.000Z</StatusDate><Source id="1146782" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-11-30T00:00:00.000Z</StatusDate><Source id="1299948" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-11-30T00:00:00.000Z</StatusDate><Source id="1299948" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-26T00:00:00.000Z</StatusDate><Source id="1352875" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-26T00:00:00.000Z</StatusDate><Source id="1352875" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-11T00:00:00.000Z</StatusDate><Source id="1390798" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-11T00:00:00.000Z</StatusDate><Source id="1390798" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-31T00:00:00.000Z</StatusDate><Source id="1384044" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-31T00:00:00.000Z</StatusDate><Source id="1384044" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-28T00:00:00.000Z</StatusDate><Source id="1353214" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-28T00:00:00.000Z</StatusDate><Source id="1353214" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1616056" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1616056" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-24T00:00:00.000Z</StatusDate><Source id="1362792" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-24T00:00:00.000Z</StatusDate><Source id="1362792" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-31T00:00:00.000Z</StatusDate><Source id="1470730" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-31T00:00:00.000Z</StatusDate><Source id="1470730" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-08-14T00:00:00.000Z</StatusDate><Source id="1523066" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-29T00:00:00.000Z</StatusDate><Source id="2038395" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-25T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-04-25T00:00:00.000Z</StatusDate><Source id="1410186" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-07-15T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-07-15T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-10T00:00:00.000Z</StatusDate><Source id="2073486" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-10T00:00:00.000Z</StatusDate><Source id="2073486" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="2073515" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="2073515" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-05-31T00:00:00.000Z</StatusDate><Source id="2073515" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-05-31T00:00:00.000Z</StatusDate><Source id="2073515" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="572056" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="622602" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="622602" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="622602" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="622602" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="622602" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-17T00:00:00.000Z</StatusDate><Source id="622602" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-04-30T00:00:00.000Z</StatusDate><Source id="855304" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1079593" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1079593" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1079593" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1079593" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1090839" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-31T00:00:00.000Z</StatusDate><Source id="1094869" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-31T00:00:00.000Z</StatusDate><Source id="1094869" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-27T00:00:00.000Z</StatusDate><Source id="734869" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-05-20T00:00:00.000Z</StatusDate><Source id="1193644" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-05-20T00:00:00.000Z</StatusDate><Source id="1193644" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-30T00:00:00.000Z</StatusDate><Source id="868428" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-04-26T00:00:00.000Z</StatusDate><Source id="787553" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1017684">Jiangsu Hansoh Pharmaceutical Group Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id=""></Indication><AwardedIndication></AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-29T00:00:00.000Z</MileStoneDate><Source id="2000737" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00721"><Name>Factor Xa</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005894">Portola Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="26891">SK Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>COc1ccc(cc1)n2c3c(c(n2)C(=O)N)CCN(C3=O)c4ccc(cc4)N5CCCCC5=O</Smiles></StructureSmiles><Deals><Deal id="109738" title="Pfizer and Bristol-Myers Squibb to codevelop and commercialize apixaban for venous and thrombotic diseases worldwide "></Deal><Deal id="142447" title="Portola to conduct clinical studies for assessing PRT-4445 as antidote to Bristol-Myers' ELIQUIS"></Deal><Deal id="142450" title="Portola to conduct clinical studies for assessing PRT-4445 as antidote to Pfizer's ELIQUIS "></Deal><Deal id="240754" title="SK Biotek to purchase manufacturing facility and supply APIs to BMS"></Deal></Deals><PatentFamilies><PatentFamily id="1041596" number="US-09549912" title="Methods for treating atrial fibrillation"></PatentFamily><PatentFamily id="108838" number="US-20070259913" title="Prophylaxis of thromboembolic events in cancer patients"></PatentFamily><PatentFamily id="1102423" number="WO-2009007028" title="Prodrug derivatives of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide"></PatentFamily><PatentFamily id="1191117" number="CN-102675314" title="Synthesis of apixaban"></PatentFamily><PatentFamily id="1260987" number="WO-2012069139" title="Analysis of direct factor Xa inhibitors"></PatentFamily><PatentFamily id="1466577" number="WO-2007001385" title="Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones"></PatentFamily><PatentFamily id="1611425" number="WO-2007022165" title="Factor Xa inhibitor formulation and method"></PatentFamily><PatentFamily id="1623765" number="WO-2007047608" title="Fibrin targeted therapeutics"></PatentFamily><PatentFamily id="1732699" number="WO-03049681" title="Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones"></PatentFamily><PatentFamily id="1916109" number="WO-2006078331" title="Crystallization via high-shear transformation"></PatentFamily><PatentFamily id="2105423" number="WO-2006110726" title="Dosage formulations and methods of treatment and prevention"></PatentFamily><PatentFamily id="2206015" number="WO-2010030983" title="Pyrazole carboxamide inhibitors of factor Xa"></PatentFamily><PatentFamily id="2428174" number="WO-2012168364" title="Apixaban preparation process"></PatentFamily><PatentFamily id="2466239" number="EP-02554159" title="Dosage forms comprising apixaban and content uniformity enhancer"></PatentFamily><PatentFamily id="255322" number="WO-2006106695" title="Highly sensitive hematological assay and reagent"></PatentFamily><PatentFamily id="2555084" number="CN-103159670" title="Synthetic method of apixaban intermediate 1-(4-nitrobenzophenone)-2-piperidone"></PatentFamily><PatentFamily id="2577783" number="WO-2013119328" title="Solid state forms of apixaban"></PatentFamily><PatentFamily id="2579428" number="WO-2013123248" title="Modulation of factor Xa inhibitor mediated blood loss by partial and transient administration of antidote"></PatentFamily><PatentFamily id="2593417" number="US-20130245267" title="Novel forms of apixaban"></PatentFamily><PatentFamily id="2626614" number="WO-2013164839" title="Amorphous form of apixaban, process of preparation and compositions thereof"></PatentFamily><PatentFamily id="263979" number="WO-00039131" title="Nitrogen containing heterobicycles as factor XA inhibitors"></PatentFamily><PatentFamily id="2641364" number="WO-2013174498" title="Dosage forms comprising apixaban and matrix former"></PatentFamily><PatentFamily id="2702563" number="CN-103626759" title="Preparation method of apixaban intermediates"></PatentFamily><PatentFamily id="2702625" number="CN-103626689" title="Preparation method of apixaban intermediates"></PatentFamily><PatentFamily id="2707955" number="CN-103539795" title="Crystalline and polymorphic forms of apixaban and its preparation method"></PatentFamily><PatentFamily id="2709304" number="WO-2014052678" title="Apixaban liquid formulations"></PatentFamily><PatentFamily id="2733705" number="WO-2014072884" title="Process for the synthesis of apixaban"></PatentFamily><PatentFamily id="2739598" number="WO-2014075648" title="Method of preparing apixaban"></PatentFamily><PatentFamily id="2748058" number="CN-103694237" title="One anti-coagulation medicine albendazole piperidine of preparation method and key intermediate of apixaban"></PatentFamily><PatentFamily id="2767486" number="EP-02752414" title="Crystalline form of apixaban"></PatentFamily><PatentFamily id="2768888" number="CN-103896940" title="Synthetic method for aripiprazole piperazine rivaroxaban"></PatentFamily><PatentFamily id="2770845" number="WO-2014108632" title="Use of factor xa in the prevention or treatment of haemorrhagic events following the taking of anticoagulants"></PatentFamily><PatentFamily id="2771232" number="WO-2014108919" title="Novel intermediate and polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof"></PatentFamily><PatentFamily id="2773547" number="WO-2014111954" title="Process for the preparation and purification of apixaban"></PatentFamily><PatentFamily id="2778930" number="CN-103833755" title="Apixaban polymorph B and preparation method thereof"></PatentFamily><PatentFamily id="2779807" number="CN-103830199" title="Composition comprising polymorph apixaban and preparation method thereof"></PatentFamily><PatentFamily id="2816257" number="CN-103923080" title="One of prepared antithrombotic drug aripiprazole piperazine apixaban and method"></PatentFamily><PatentFamily id="2816258" number="CN-103923079" title="Preparation method of apixaban intermediate"></PatentFamily><PatentFamily id="2823383" number="WO-2014173377" title="New crystalline forms of apixaban and a method of their preparation"></PatentFamily><PatentFamily id="2832033" number="CN-103992314" title="Synthetic method of anticoagulation drug apixaban  "></PatentFamily><PatentFamily id="2851091" number="WO-2014203275" title="An improved process for the preparation of apixaban and intermediates thereof"></PatentFamily><PatentFamily id="2856295" number="CN-104086544" title="Opioid apixaban monohydrate and preparation method thereof and pharmaceutical composition"></PatentFamily><PatentFamily id="2878887" number="CN-104262338" title="A apixaban and synthesizing method of intermediate thereof"></PatentFamily><PatentFamily id="2917541" number="CN-104382874" title="One kind of apixaban sustained-release tablets and preparation method"></PatentFamily><PatentFamily id="2927967" number="CN-104523623" title="Apixaban dripping pill and its preparation method "></PatentFamily><PatentFamily id="2928888" number="WO-2015066700" title="Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation"></PatentFamily><PatentFamily id="2929209" number="WO-2015066606" title="Compositions and methods for increasing the half-life of Factor Xa"></PatentFamily><PatentFamily id="2931671" number="CN-104490841" title="A apixaban tablet and preparation method thereof"></PatentFamily><PatentFamily id="2931678" number="CN-104490834" title="A preparation method of apixaban tablet"></PatentFamily><PatentFamily id="2951370" number="CN-104523619" title="An apixaban tablet and preparation method thereof"></PatentFamily><PatentFamily id="2953961" number="CN-104650074" title="One kind of apixaban compound"></PatentFamily><PatentFamily id="2954950" number="CN-104644593" title="Apixaban composition and preparation method thereof"></PatentFamily><PatentFamily id="2955671" number="CN-104628724" title="A apixaban preparation method"></PatentFamily><PatentFamily id="2958724" number="WO-2015086618" title="Identification of anticoagulants in a sample"></PatentFamily><PatentFamily id="2966922" number="WO-2015097090" title="Oral pharmaceutical composition"></PatentFamily><PatentFamily id="2977888" number="WO-2015111073" title="A process for the preparation of apixaban and its intermediates"></PatentFamily><PatentFamily id="2982954" number="CN-104788448" title="Apixaban crystal form and preparation method thereof"></PatentFamily><PatentFamily id="3032925" number="CN-104892601" title="Preparation method of an antithrombotic drug apixaban"></PatentFamily><PatentFamily id="3042030" number="CN-104910147" title="Piperazine apixaban aripiprazole crystal and its preparation method"></PatentFamily><PatentFamily id="3058569" number="WO-2015162551" title="Process for the preparation of apixaban"></PatentFamily><PatentFamily id="3071108" number="WO-2015177293" title="Assay to determine anticoagulants in blood or blood plasma"></PatentFamily><PatentFamily id="3071200" number="WO-2015177801" title="Novel process for the preparation of a lactam-containing compound"></PatentFamily><PatentFamily id="3075236" number="CN-105037349" title="A gamma crystal form apixaban and its preparation method"></PatentFamily><PatentFamily id="3079319" number="WO-2015183085" title="Prohemostatic proteins for the treatment of bleeding"></PatentFamily><PatentFamily id="3106758" number="WO-2016005560" title="Process for preparing apixaban"></PatentFamily><PatentFamily id="3108442" number="CN-105218544" title="One synthesis method of aripiprazole piperazine apixaban intermediate"></PatentFamily><PatentFamily id="3127155" number="CN-105254630" title="Preparation method for apixaban"></PatentFamily><PatentFamily id="3159359" number="CN-104387383" title="Synthetic method of novel apixaban precursor compound"></PatentFamily><PatentFamily id="3176064" number="CN-105503859" title="Method of purifying apixaban"></PatentFamily><PatentFamily id="3185745" number="IN-201403510" title="Preparing apixaban to prevent venous thromboembolic events, comprises e.g. reacting comprises e.g. methoxy phenyl hydrazono chloro carboxylic acid ester"></PatentFamily><PatentFamily id="3190940" number="TW-201605851" title="A process for preparing crystalline forms of apixaban"></PatentFamily><PatentFamily id="3196093" number="US-09603846" title="Process for the preparation of apixaban"></PatentFamily><PatentFamily id="3203181" number="WO-2015018289" title="Novel method for synthesizing key intermediate of apixaban"></PatentFamily><PatentFamily id="3207179" number="CN-105596309" title="Apixaban sustained release tablet and preparation method thereof"></PatentFamily><PatentFamily id="3211526" number="IN-201300639" title="Preparing apixaban involves reacting aniline compound with piperidin-2-one compound, reacting hydrazone compound with piperidin-2-one compound, converting pyridine-3-carboxylate compound to apixaban, and optionally, purifying apixaban"></PatentFamily><PatentFamily id="3226346" number="CN-105663049" title="Sustained-release pellets apixaban and its preparation method"></PatentFamily><PatentFamily id="3234185" number="CN-105712990" title="Apixaban intermediates preparation"></PatentFamily><PatentFamily id="3239832" number="CN-105732622" title="A preparation method of apixaban"></PatentFamily><PatentFamily id="3246075" number="US-20160206754" title="Molecular constructs for treating tumors"></PatentFamily><PatentFamily id="3314663" number="CN-105832672" title="Preparation method and application of solid dispersion"></PatentFamily><PatentFamily id="3334033" number="CN-103342704" title="In one method of anti-thrombotic drug aripiprazole apixaban of piperazine"></PatentFamily><PatentFamily id="3334196" number="CN-103360391" title="Aripiprazole piperazine rivaroxaban new crystal form and preparation method thereof"></PatentFamily><PatentFamily id="3352286" number="WO-2017013079" title="Dimer impurities of apixaban and method to remove them"></PatentFamily><PatentFamily id="3392003" number="WO-2011106478" title="Apixaban formulations"></PatentFamily><PatentFamily id="3395579" number="CN-105943536" title="Preparation method of a solid dispersion and its use"></PatentFamily><PatentFamily id="3396743" number="IN-201500807" title="Preparation of apixaban involves reacting ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1h-(3,4-c)pyridine-3-carboxylate with piperidin-2-one in the presence of alkali metal carbonate salt and reacting with ammonia"></PatentFamily><PatentFamily id="3403055" number="CN-105175415" title="&lt;para&gt;Preparation method of two-crystal-water-containing crystal form of apixaban&lt;/para&gt;"></PatentFamily><PatentFamily id="3428195" number="CN-106008497" title="Apixaban polymorph and its preparation method"></PatentFamily><PatentFamily id="3428778" number="CN-105997883" title="Solid dispersion, preparation method and application thereof"></PatentFamily><PatentFamily id="3429361" number="CN-105985336" title="Preparation method of aripiprazole crystal form piperazine, edoxaban n-1"></PatentFamily><PatentFamily id="3429703" number="CN-105982870" title="Apixaban tablet"></PatentFamily><PatentFamily id="3445972" number="IN-201502162" title="Oral dosage form composition useful for reducing risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, comprises apixaban, diluents, disintegrants, and lubricants"></PatentFamily><PatentFamily id="3456486" number="CN-106117201" title="Preparation method of an antithrombotic drug apixaban"></PatentFamily><PatentFamily id="3456487" number="CN-106117200" title="Preparation method of prevention or treatment of joint replacement venous thrombosis medicine edoxaban"></PatentFamily><PatentFamily id="3513620" number="CN-106279149" title="A method for preparing high-purity apixaban"></PatentFamily><PatentFamily id="3535551" number="US-10208036" title="Process for the preparation of apixaban and intermediates thereof"></PatentFamily><PatentFamily id="3554565" number="IN-201502936" title="A process for the preparation of apixaban or its pharmaceutical acceptable salts thereof"></PatentFamily><PatentFamily id="3568219" number="CN-106420651" title="A preparation method of apixaban tablet"></PatentFamily><PatentFamily id="3583788" number="CN-106496221" title="A method for preparing apixaban form N-1"></PatentFamily><PatentFamily id="3589577" number="CN-106518867" title="A method for refining piperazine, edoxaban"></PatentFamily><PatentFamily id="3613452" number="CN-106562981" title="Non apixaban and pharmaceutical composition and application of ginsenoside Rb3"></PatentFamily><PatentFamily id="3635537" number="IN-201504138" title="An improved process for preparation of 3, 3-dichloro-1-(4-iodophenyl) piperidin-2-onean apixaban intermediate"></PatentFamily><PatentFamily id="3635539" number="IN-201504137" title="An improved process for preparing intermediate of apixaban"></PatentFamily><PatentFamily id="3637818" number="CN-106632312" title="A apixaban related substance, intermediate, preparation method and application thereof"></PatentFamily><PatentFamily id="3652016" number="WO-2017088841" title="Preparation of a drug form containing amorphous apixaban"></PatentFamily><PatentFamily id="3698548" number="CN-106822006" title="Apixaban tablet and its preparation method"></PatentFamily><PatentFamily id="370745" number="WO-2010147978" title="Dosage forms of apixaban"></PatentFamily><PatentFamily id="3711638" number="CN-106860868" title="Pharmaceutical composition of apixaban drugs and lumbrokinase, preparation and application thereof"></PatentFamily><PatentFamily id="3721883" number="IN-201504893" title="Process for the preparation of anhydrous crystalline form of apixaban"></PatentFamily><PatentFamily id="3721963" number="IN-201503987" title="Solid oral composition used to treat thromboembolic disorder, comprises mixture of coarser fraction and finer fraction of apixaban having specific particle size distribution in specific weight ratio, and excipient"></PatentFamily><PatentFamily id="3722270" number="CN-106902115" title="Use of apixaban in the medicine for treating diabetic foot"></PatentFamily><PatentFamily id="3725798" number="WO-2017121340" title="Araxaban solid composition and preparation method therefor"></PatentFamily><PatentFamily id="3730585" number="CN-106928220" title="A group of apixaban impurities"></PatentFamily><PatentFamily id="3730840" number="CN-106913528" title="Apixaban micro-pill and preparation method thereof"></PatentFamily><PatentFamily id="373116" number="CN-101967145" title="A method for preparing antithrombotic drug apixaban"></PatentFamily><PatentFamily id="3737711" number="WO-2017125535" title="Method for producing an apixaban granulate"></PatentFamily><PatentFamily id="3754627" number="CN-106986868" title="Comprises an opioid apixaban eutectic and preparation method thereof"></PatentFamily><PatentFamily id="3799476" number="WO-2017163170" title="Pharmaceutical composition comprising apixaban"></PatentFamily><PatentFamily id="3815081" number="EP-03228619" title="Process for the preparation of apixaban"></PatentFamily><PatentFamily id="3821265" number="WO-2017180683" title="Prevention of atherosclerotic events with direct factor Xa inhibitors"></PatentFamily><PatentFamily id="3828518" number="WO-2017182908" title="Pharmaceutical compositions of apixaban"></PatentFamily><PatentFamily id="3834660" number="WO-2017187245" title="An improved process for the preparation of apixaban"></PatentFamily><PatentFamily id="3842542" number="IN-201621001853" title="Preparing composition comprising e.g. apixaban, used to treat thromboembolic disorder, comprises spraying or sprinkling binder solution comprising e.g. apixaban on dry mix blend comprising diluent, disintegrant and/or surfactant, and drying"></PatentFamily><PatentFamily id="3847914" number="WO-2017194876" title="Universal calibration method for the dosing of enzymatic inhibitors"></PatentFamily><PatentFamily id="3848409" number="WO-2017197332" title="Compositions and methods for anti-thrombotic and hemostatic therapies"></PatentFamily><PatentFamily id="3848937" number="EP-03243505" title="A pharmaceutical composition comprising amorphous apixaban"></PatentFamily><PatentFamily id="3875690" number="IN-201641006652" title="Solid mouth dissolving pharmaceutical composition of apixaban used for treating e.g. unstable angina and acute coronary syndrome comprises apixaban, diluent, disintegrant, binder, lubricant, and/or any other excipient"></PatentFamily><PatentFamily id="3878823" number="CN-107400131" title="Opioid apixaban derivative, preparation method and application thereof"></PatentFamily><PatentFamily id="3884461" number="CN-107434806" title="Apixaban carboxylic acid derivative of γ-crystal solid substance and preparation method and use thereof"></PatentFamily><PatentFamily id="3894776" number="WO-2017221209" title="Pharmaceutical formulations of apixaban"></PatentFamily><PatentFamily id="3952659" number="CN-107663205" title="A method for refining apixaban"></PatentFamily><PatentFamily id="3953064" number="CN-107661301" title="Apixaban pharmaceutical composition and preparation method thereof"></PatentFamily><PatentFamily id="3968920" number="CN-107703234" title="Headspace sample gas phase chromatography residual solvent method, edoxaban"></PatentFamily><PatentFamily id="3981120" number="WO-2017036407" title="Molecular constructs for treating rejection reaction in transplantation"></PatentFamily><PatentFamily id="4024894" number="CN-107898824" title="Apixaban tablet"></PatentFamily><PatentFamily id="4031416" number="CN-107955003" title="A edoxaban intermediate 2 the synthesis process method for removing specific impurities s4"></PatentFamily><PatentFamily id="4031417" number="CN-107955002" title="Opioid apixaban and intermediates thereof"></PatentFamily><PatentFamily id="4033553" number="CN-107936016" title="After preventing hip and knee replacement surgery venous thrombosis of drug preparation method of edoxaban intermediate"></PatentFamily><PatentFamily id="4033554" number="CN-107936015" title="A N-1 crystalline form of apixaban of synthesis method"></PatentFamily><PatentFamily id="4055312" number="CN-107991412" title="High performance liquid chromatography measuring method of apixaban impurity content"></PatentFamily><PatentFamily id="4090121" number="CN-108129477" title="A edoxaban BMS-591329 impurity in raw material medicine cleaning method"></PatentFamily><PatentFamily id="4098550" number="CN-108164526" title="A preparation method of piperazine, edoxaban impurity b"></PatentFamily><PatentFamily id="4110045" number="CN-108178757" title="A preparation method of edoxaban for treatment of deep vein thrombosis and pulmonary embolism diseases"></PatentFamily><PatentFamily id="4122306" number="WO-2018127936" title="Novel economic metal free process for apixaban"></PatentFamily><PatentFamily id="4124601" number="CN-108236604" title="Opioid edoxaban flexible lipidosome"></PatentFamily><PatentFamily id="4149042" number="CN-108329314" title="A micro-channel reactor to synthesize piperazine edoxaban intermediate of method"></PatentFamily><PatentFamily id="4166953" number="WO-2018150286" title="Pharmaceutical composition of apixaban"></PatentFamily><PatentFamily id="4183265" number="WO-2018158620" title="Preparation of active pharmaceutical ingredients and intermediates thereof"></PatentFamily><PatentFamily id="4193606" number="CN-108503580" title="A preparation method of piperazine apixaban intermediate"></PatentFamily><PatentFamily id="420829" number="WO-2006045756" title="Use of dipyridamole in combination with antithrombotics for treatment and prevention ofthromboembolic diseases"></PatentFamily><PatentFamily id="4208707" number="CN-108558741" title="A edoxaban of intermediate synthesis method"></PatentFamily><PatentFamily id="4232430" number="CN-108645933" title="Opioid edoxaban raw materials in residual solvent gas chromatography detecting method"></PatentFamily><PatentFamily id="4258447" number="IN-201741013582" title="Preparing substituted 3,3-dichloro-1-phenyl-piperidin-2-one comprises reacting substituted 1-phenyl-piperidin-2-one with a chlorinating agent in the absence of a solvent"></PatentFamily><PatentFamily id="4297950" number="CN-108864090" title="A edoxaban N-1 crystal preparation method"></PatentFamily><PatentFamily id="4308627" number="CN-108912119" title="A edoxaban ring-opening acid impurities and its preparation method"></PatentFamily><PatentFamily id="4309758" number="CN-108904461" title="Preparation method of apixaban tablet"></PatentFamily><PatentFamily id="4336577" number="CN-109030655" title="A fast measuring content of apixaban method"></PatentFamily><PatentFamily id="4337570" number="CN-109020874" title="A edoxaban intermediate and preparation method thereof"></PatentFamily><PatentFamily id="4339105" number="CN-109010273" title="Apixaban nanosuspension and preparation method thereof"></PatentFamily><PatentFamily id="4379795" number="WO-2019023508" title="Methods and devices for detection of anticoagulants in plasma and whole blood"></PatentFamily><PatentFamily id="4388646" number="WO-2019027853" title="Detection of high risk arterial thromboembolic diseases by markers of coagulation and hemostatic activation"></PatentFamily><PatentFamily id="4450502" number="CN-109464415" title="Apixaban medicine composition and its preparation method"></PatentFamily><PatentFamily id="446309" number="US-20090076069" title="Deuterium-enriched apixaban"></PatentFamily><PatentFamily id="4469586" number="CN-109528674" title="A apixaban containing hydrophilic form of pharmaceutical composition and its preparation method"></PatentFamily><PatentFamily id="4482325" number="CN-109627242" title="Preparation method of apixaban"></PatentFamily><PatentFamily id="4496060" number="WO-2019088838" title="Method for determining factor Xa inhibitor dosage"></PatentFamily><PatentFamily id="4528436" number="CN-109793715" title="A apixaban oral solid preparation and preparation method thereof"></PatentFamily><PatentFamily id="570564" number="WO-03026652" title="Lactam-containing compounds and derivatives thereof as factor Xa inhibitors"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>39</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>26</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>21</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>69</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>10</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intel Corp" id="1002235"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Straumann Holding AG" id="1002374"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="East China University of Science &amp; Technology" id="1004888"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang Pharmaceutical University" id="1004998"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Portola Pharmaceuticals Inc" id="1005894"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ScinoPharm Taiwan Ltd" id="1006516"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qilu Pharmaceutical Co Ltd" id="1006577"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Unichem Laboratories Ltd" id="1008072"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hikal Ltd" id="1008476"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Pharmaceutical Co Ltd" id="1009275"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Yangzijiang Pharmacy" id="1010453"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emcure Pharmaceuticals Ltd" id="1010536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zafena AB" id="1011548"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fabbrica Italiana Sintetici SpA" id="1014135"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amoli Organics Ltd" id="1015262"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Fosun Pharmaceutical (Group) Co Ltd" id="1015871"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Shyndec Pharmaceutical Co Ltd" id="1015980"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Hansoh Pharmaceutical Group Co Ltd" id="1017684"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan University (Guangdong)" id="1019449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SMS Pharmaceuticals Ltd" id="1022917"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MSN Laboratories Ltd" id="1025511"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Bai'ao Pharmaceutical Co Ltd" id="1027650"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kangli Pharmaceutical Company Ltd" id="1027773"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Pharmaceutical Industrial Group Co Ltd" id="1027902"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="HEC Pharm Co Ltd" id="1028084"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Indoco Remedies Ltd" id="1028190"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang East-Asia Pharmaceutical Chemical Co Ltd" id="1028850"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wanbury Ltd" id="1029031"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebei Changshan Biochemical Pharmaceutical Co Ltd" id="1029969"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ABA Chemicals (Shanghai) Ltd" id="1030180"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Pharmaceutical Group Co Ltd" id="1030330"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Jingxin Pharmaceutical Co Ltd" id="1030336"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Tianyu Pharmaceutical Co Ltd" id="1030351"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Institute of Pharmaceutical Research" id="1031863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangnan University" id="1043874"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Cavendish Bio-Engineering Technology Co Ltd" id="1044033"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Winsunny Pharmaceutical Co Ltd" id="1045068"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Haoyuan Chemexpress Co Ltd" id="1053356"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aizant Drug Research Solutions Private Ltd" id="1053643"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Luoxin Pharmaceutical Group Stock Co Ltd" id="1054140"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang J &amp; Health Pharmaceutical Co Ltd" id="1054192"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Invent Farma ehf" id="1063377"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Hankang Pharmaceutical Biotechnology" id="1065273"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Good Biomarker Sciences Bv" id="1067491"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Zhengke Pharmaceutical Co Ltd" id="1068599"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Haoyuan Group" id="1072452"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Optimus Pharma Pvt Ltd" id="1072625"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Armetheon Inc" id="1073039"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SFFT Developing Co Ltd" id="1073083"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Tianyitang Pharmaceutical Co Ltd" id="1073311"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Hicin Pharmaceutical Co Ltd" id="1075300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai SynCores Technologies Inc" id="1076463"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shaanxi University of Science &amp; Technology" id="1077449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ChemFuture Pharmatech (Jiangsu) Ltd" id="1079808"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gansu Haotian Chemexpress Co Ltd" id="1082195"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chengdu Brilliant Pharmaceutical Co Ltd" id="1083125"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Jingxin Biopharmaceutical Co Ltd" id="1084946"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Su Zhou Jing Hong Biotech Co Ltd" id="1085409"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Bozhi Research Of New Drugs Technology Co Ltd" id="1085772"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Henan Runhong Pharmaceutical Co Ltd" id="1087091"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taikomed Pharmaceutical Co Ltd" id="1088938"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Catalyst/The Harvard Clinical and Translational Science Center" id="1094393"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Landan Pharmaceutical Technology Co Ltd" id="1098743"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing Toptech Pharmaceutical Co Ltd" id="1099626"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangdong Yihao Pharmaceutical Co., Ltd." id="1102497"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harbin Shengji Pharmaceutical Co Ltd" id="1108717"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Yiyao Technology Co Ltd" id="1109826"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shui Tianjin Pharmaceutical Co Ltd" id="1110253"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Zhongbang Pharmaceutical Co Ltd" id="1111446"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lepu Pharmaceutical Co Ltd" id="1122841"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qingdao Yuntian Biotechnology Co Ltd" id="1123580"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immunwork Inc" id="1127026"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Triwin Pharmaceutical Technology Co Ltd" id="1128715"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Sungening Biotechnology Co Ltd" id="1129746"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Optimus Drugs Pvt Ltd" id="1130431"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alliance Medical Group" id="1148001"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stago International SAS" id="1148740"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adams Pharmaceuticals Llc" id="1155411"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Zhicheng Pharmaceutical Co Ltd" id="1157287"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heilongjiang Xinchuang Biotechnology Development Co Ltd" id="1174241"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Baozhong And Baoda Pharmaceutical Co. Ltd." id="1176537"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuxi Kaifu Pharmaceutical Co. Ltd." id="1180392"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royal DSM NV" id="15823"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Dr Esteve SA" id="16074"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kissei Pharmaceutical Co Ltd" id="17665"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="EPIX Pharmaceuticals Inc" id="18201"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Massachusetts Institute of Technology" id="18225"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gedeon Richter Ltd" id="19441"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stada Arzneimittel AG" id="20236"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emory University" id="20573"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universiteit Leiden" id="20603"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Childrens Hospital of Philadelphia" id="21052"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Scripps Research Institute" id="21102"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharmaceutical University" id="21231"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LFB SA" id="25256"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dinamite Dipharma SpA" id="26954"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ARYx Therapeutics Inc" id="27242"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Heidelberg" id="28348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Academia Sinica" id="28429"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zydus-Cadila Group" id="29062"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Torrent Pharmaceuticals Ltd" id="29175"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aurobindo Pharma Ltd" id="30215"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Kanion Pharmaceutical Co Ltd" id="30980"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johannes Gutenberg Universitat Mainz" id="DOL1000148"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>